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ABSTRACT
BRCA1 and BRCA2 are gene mutations that drastically increase chances of develop-
ing breast and ovarian cancers, up to 20-fold, for women. A genetic blood test is used to
detect BRCA mutations. Though these mutations occur in one of every 400 in the general
population (excluding Ashkenazi Jewish ethnicity), they are present in most cases of hered-
itary breast and ovarian cancer patients. Hence, it is common practice for the physicians to
require genetic testing for those that ﬁt the rules as recommended by the National Cancer
Comprehensive Network. However, data from the Myriad Laboratory, the only provider of
the test until 2013, show that over 70 percent of those tested are negative for BRCA muta-
tions [1]. As there are signiﬁcant costs and psychological trauma associated with having to
go through the test, there is a need for more comprehensive rules for determining who should
be tested. Once the presence of BRCA is identiﬁed via testing, the next challenge for both
mutation carriers and their physicians is to select the most appropriate types and timing
of intervention actions. Organizations such as the American Cancer Society suggest drastic
intervention actions such as prophylactic surgeries and intense breast screenings. These ac-
tions vary signiﬁcantly in their cost, cancer incidence prevention ability, and can have major
side eﬀects potentially resulting in reproduction inability or death. Eﬀectiveness of these
intervention actions is also age dependent.
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In this dissertation, both an analytical and an optimization framework are presented.
The analytical framework uses supervised machine learning models on extended family his-
tory of cancers, and personal and medical information from a recent nationwide survey study
of women who have been referred for genetic testing for the presence of a BRCA mutation.
This framework provides the potential mutation carriers as well as their physician with
an estimate of the likelihood of having the mutations. The optimization framework uses
a Markov decision process (MDP) model to ﬁnd cost-optimal and/or quality-adjusted life
years (QALYs) optimal intervention strategies for those tested positive for a BRCA muta-
tion. This framework uses a dynamic approach to address this problem. The decisions are
made more robust by considering the variation in estimates of the transition probabilities
by using a robust version of the MDP model.
This research study delivers an innovative decision support tool that enables physicians
and genetic consultants predict the population at high risk of breast and ovarian cancers more
accurately. For those identiﬁed with presence of the BRCA mutation, the decision support
tool oﬀers eﬀective intervention strategies considering either minimizing cost or maximizing
QALYs to prevent incidence of cancers.
vi
CHAPTER 1: INTRODUCTION
Early detection of women at high risks of developing breast and ovarian cancers is
considered as one of the critical issues in health care. National Cancer Institute (NCI)
reported that BRCA1 and BRCA2 gene mutations are accountable for up to 25% and 15%
of hereditary breast and ovarian cancer cases, respectively [2]. Based on this report women
with BRCA gene mutations have up to 65% and 17% chances of developing breast and
ovarian cancers, respectively, compared to 12% and 1.3% chances in the general population,
by age 70. BRCA gene mutations may also be associated with increased risks of developing
other cancers such as pancreatic, fallopian tube, and peritoneal cancers [2].
BRCA gene mutations are dominant genes that can be passed from an aﬀected parent
to their children. It is often assumed that an aﬀected parent has 50% chance of passing the
gene to their children regardless of their genders. Given these facts, BRCA gene mutations
are mostly seen in families with hereditary breast and ovarian cancers.
There are several tools available to help individuals as well as health practitioners
to estimate one’s likelihood of having BRCA mutations based on family history of cancers
and individual’s personal and medical history. National Cancer Comprehensive Network
(NCCN) also has guidelines for physicians to refer individuals at high risk of familial breast
and ovarian cancers for genetic BRCA testing. A BRCA genetic blood test can detect the
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existence of these mutations in an individual. However, this process is costly and based on
the Myriad Laboratory report, most people tested are identiﬁed with negative test results [1].
1.1 Literature Review
Literature related to ﬁnding the likelihood of having a BRCA mutation comprised
of empirical and Mendelian models. Stratiﬁcation by family or personal history is used
for empirical models such as Penn [3], Manchester [4], and Frank-Myriad [5]. Whereas,
Mendelian models such as BRCAPRO [6] and IBIS [7], are based on Bayesian statistical
models given the Mendelian genetic rules of mutation transition.
Empirical models are simple and easy to use. However, for building an accurate empir-
ical model, a large number of samples is needed. Moreover, the rules used for building such
models are generalized. For example, family history of cancer is based on the ‘total number
of cases’ in the family instead of individual cases. Mendelian models are more complicated
and accurate than empirical models, but they are based on prior probability estimations
such as penetrances and allele frequencies which are often underestimated [8] [9]. A more
detailed discussion of the models is explained in details in Chapter 2.
In 2004, Marroni et al. compared eight of the existing empirical and Mendelian models
for 568 families [9]. The authors concluded that Mendelian models are more accurate overall
for predicting the total number of cases with mutations compared to empirical models.
However, all the eight models underestimated the likelihood of having mutations in the
lower risk population and overestimated individuals at high risk.
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In 2008, Antoniou et al. studied the ﬁve most recent models for likelihood prediction
of BRCA mutations [10]. They concluded that all the models underpredict families with
low risk of having a BRCA mutation, which is a large proportion of their study population.
Most of these ﬁndings, however, are based on populations recruited academically in research
centers. Therefore, performances of these models have not been tested yet in the wider
population.
In 2011, American BRCA Outcomes and Utilization of Testing (ABOUT) collected
nation-wide data from women for whom BRCA testing was requested through a commercial
health insurance company [11]. In Chapter 2, the author explains how this data was used
to build a novel model using machine learning techniques for estimating likelihood of having
a BRCA mutation. Participants of this study have been asked to provide their detailed
information of paternal and maternal family histories of cancers as well as their own medical
and cancer history information. The proposed approach, free of assumptions of Mendelian
models, provide a new and in some cases more accurate way of classifying aﬀected individuals.
The next challenge for individuals tested positive for a BRCA gene mutation is to ﬁnd
the best timing and type of eﬀective intervention actions for preventing breast and ovarian
cancers. The appropriate types of actions based on American Cancer Society guidelines are
drastic [12]. The screening action recommended is a combination of mammography and
magnetic resonance imaging (MRI). Cancer preventive surgeries recommended are prophy-
lactic mastectomy, in which both breasts are removed and prophylactic oophorectomy in
which both ovaries are removed. The costs of these actions diﬀer signiﬁcantly and their
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eﬀectiveness changes with time. The open literature oﬀers a handful of simulation driven
Markov models that are designed to evaluate ad hoc strategies (sequence of intervention
actions) with respect to cost [13] and survival [14]. These simulation-based studies use sen-
sitivity analysis to assess the impact of uncertainties of the input parameters. However,
a comprehensive model to select an optimal intervention strategy from the strategy space
has not been discussed in the literature. Such a model based tool should have the ability
to consider various health state-dependent intervention action choices, their time-dependent
impact on health state transition probabilities, and their expected costs and utilities. In this
dissertation, the Appendix B presents a published paper entitled A MDP model for breast
and ovarian cancer intervention strategies for BRCA1/2 mutation carriers. In Chapter 3,
Markov decision process (MDP) models capable of determining optimal policies in terms
of cost and quality-adjusted life-years (QALYS) is presented. The recommendations by the
MDP models can be used as a guideline for both patients and policy holders to make more
informed decisions.
Furthermore, to study the eﬀect of estimation errors in measurement of transition
probabilities obtained from a simulation study [14], a robust MDP framework is built and
tested. The most common way used in the literature for analyzing such uncertainty is
sensitivity analysis of speciﬁc parameters in the model. However, this ad hoc approach is
not fully capable of incorporating the aggregate eﬀect of uncertainties from all the parameter
estimations in the model [15]. There have been several papers published in the literature
studying the eﬀect of uncertainty in the transition probabilities estimation in a MDP model
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[16] [17] [18]. The three main ways to consider uncertainty in MDP models are: a Bayesian
approach, an interval approach, and a likelihood based approach. A Bayesian deﬁnition
of uncertainty proposed by Shapiro et al. [19] is based on a complete knowledge of prior
transition probabilities, which often is not the case in practice [17]. Also, an interval approach
often leads to a poor statistical representation of uncertainty and very conservative policies.
Therefore, in this dissertation a statistically more accurate deﬁnition of uncertainty using
a likelihood approach proposed by Nilim et al. in 2004 is used [20]. The robust optimal
intervention actions are obtained by minimizing/maximizing the expected total cost/reward
under the worst-case scenario played by nature. The robust MDP cost-optimal and QALYs-
optimal models are presented in more detail in Chapter 4 of this dissertation.
1.2 Research Contributions
The research contributions of the work presented in Chapters 2, 3, and 4 are described
next.
Chapter 2 includes the following:
• A more accurate risk estimator model is developed for ﬁnding the likelihood of
having a BRCA gene mutation given family and personal history of cancers using a
gradient boosting model.
• The existing and widely used BRCA likelihood estimation models by genetic con-
sultants are compared with a recent large nation-wide survey data of American women
who have undergone BRCA genetic testing.
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• Recent and powerful machine learning models such as random forest, regularized
logistic regression, and support vector machines are evaluated and compared with the
well-known Bayesian and empirical BRCA risk estimators models in the literature.
Chapter 3 includes the following:
• A cost-optimal model is presented for policy holders capable of ﬁnding optimal
intervention strategies to prevent breast and ovarian cancers for all ages between 30
and 65 for BRCA1 and BRCA2 mutation carriers.
• A QALYs-optimal model is presented capable of ﬁnding optimal intervention
strategies to prevent breast and ovarian cancers for all ages between 30 and 65 for
BRCA1 and BRCA2 mutation carriers.
Chapter 4 includes the following:
• A more reliable optimization model is developed for ﬁnding eﬀective cost and
QALYs optimal preventive actions for all ages between 30 and 65 for BRCA1 and
BRCA2 mutation carriers using a robust MDP model.
1.3 Research Methods
The summary of research methodologies used in this dissertation for Chapters 2, 3,
and 4 is explained next.
1.3.1 A Likelihood Estimation of Having a BRCA Mutation
In this section, the models described in Chapters 2, 3, and 4 of this dissertation are
summarized. The ﬁrst model for ﬁnding the likelihood of having a BRCA gene mutation
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based on a family history of cancers uses a statistical-machine learning framework. This
model will provide a guideline for referring an individual for a BRCA genetic testing.
In this dissertation, the state of the art models in the literature are ﬁrst validated using
the dataset from a nationwide study in the United States conducted by American BRCA
Outcome and utilization of testing. These models are based on empirical or Mendelian
frameworks. Then machine learning classiﬁers will be built using all the information captured
in the survey conducted by ABOUT study on individual’s personal and family history of
cancers. The models considered in this dissertation consist of gradient boosting model,
random forest, support vector machines, and regularized logistic regression. The data have
only 9% positive BRCA test results compared to 91% negative results. Since, this data suﬀers
from class imbalance, in order to compare the performance of the models, area under the
ROC curve, F1-measure, Mathew correlation coeﬃcient, and the area under the precision-
recall curve were used. The machine learning classiﬁers are explained next.
Gradient boosting model (GBM) is a machine learning classiﬁer which uses an ensem-
ble of weak learners, such as decision trees, iteratively to make a prediction model. In each
iteration it gives more weight to misclassiﬁed data points. In 2002, the ﬁrst paper on stochas-
tic gradient boosting was published [21]. It has been widely used since then in the machine
learning community and has been recently applied in medical literature [22] [23] [24]. The
GBM has more prediction accuracy than decision trees, but it is less interpretable. However,
there are measures that can be used to simplify the results of a GBM. Variable importance is
one of these tools. Variable importance is proportional to the number of times a variable is
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used for splitting weighted by the model improvement. The higher importance corresponds
to higher impact on the response variable [25]. The GBM achieves the best outcome results
based on the performance criteria as explained in more details in Chapter 2.
Random forest algorithm was developed in 2001 [26]. It is an ensemble of decision
trees and uses majority of votes or mode for prediction. It selects a random sample of
training data with replacement to build the trees at each iteration. When building a tree,
random forest selects a set of covariates at random as splitting candidates for branches.
This model is robust to outliers, simple, and can be implemented using parallel computing
techniques [26]. It has been used widely in the recent medical literature for classiﬁcation
problems [27] [28] [29]. This method has been implemented for predicting disease risk with
an imbalance dataset [28]. The random forest package in R has been reported as the best
classiﬁer technique in terms of accuracy when compared with the other 179 classiﬁers from
a wide range of statistical and machine learning methods [30]. More details on parameter
tuning and implementation of this method on ABOUT study data are explained in Chapter
2.
Support vector machines (SVMs) are supervised machine learning classiﬁers. The
current version of SVMs are ﬁrst published in 1995 [31]. SVMs project the input to a higher
dimensional space through a linear or non-linear kernel function and ﬁnd a linear separator
for classiﬁcation problem [32]. This method has a good accuracy and can eﬀectively combine
features. SVM is widely used in the classiﬁcation problems and has been applied in medical
literature [32] [33] [34] [35].
8
Given the training data (xi, yi), where yi ∈ (−1,+1), the SVM algorithm ﬁnds the
linear separator as shown in Equation 1.1.
w · z + b = 0 (1.1)
In Equation 1.1, b is the constant term and z is the projected vector space. The coeﬃcient
w is found using:
w =
∑
i
αiK(si, z)yi (1.2)
In Equation 1.2, αi is the coeﬃcient, si is the support vector, and K(s,z) is the kernel function.
This algorithm is discussed in more details in [36]. In Chapter 2 of this dissertation, SVM
is applied to the ABOUT study data and is compared with other statistical and machine
learning models.
Logistic regression is considered as one of the most popular statistical methods for
classiﬁcation in medical literature [37]. For classiﬁcation problems with many features, to
avoid over-ﬁtting, a regularized version of logistic regression is often used [38]. Logistic
regression solves the problem in Equation 1.3.
p(y = 1|θ, x) = 1
1 + exp(−θTx) (1.3)
In Equation 1.3, θ represents the parameter of the logistic regression and (x, y), are the data
points, in which the binary response variable is y ∈ (0, 1). A maximum likelihood estimation
is used to ﬁnd the parameters of a logistic regression problem.
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A regularized logistic regression adds a constraint to Equation 1.3 that limits the
number of parameters that can take non-zero values in the model. Equation 1.3 uses a
L1-norm constraint on the number of parameters as shown in Equation 1.4.
min
θ
−
∑
log(p(y = 1|θ, x)) + β||θ||1 (1.4)
More details on this method can be found in [38]. In Chapter 2, the implementation of this
method on ABOUT study data is explained in more details.
1.3.2 A MDP Model to Find Optimal Cancer Prevention Strategies for BRCA
Mutation Carriers
In this section, an optimization framework is implemented to ﬁnd cost-optimal and
quality-adjusted life year-optimal intervention strategies for BRCA gene mutation carriers.
A Markov decision process (MDP) is used to model this problem. The state of a BRCA
mutation carrier in the MDPmodel is deﬁned by her age, health status, and prior intervention
action history. The value iteration algorithm is utilized to ﬁnd the optimal intervention
strategies for policy makers using cost and for BRCAmutation carriers using quality-adjusted
life years. The value iteration algorithm used to solve this MDP problem in Appendix B is
described next. The steps for solving a MDP model with a value iteration algorithm are:
Step 1. Set iteration n = 0,  > 0, and value at state s, Vn(s) = 0 ∀s ∈ S.
Step 2. For each state, s ∈ S, update the value by using:
Vn+1(s) = min
d∈Ds
{c(s, d) + (1− α)
∑
j∈S
p(j|s, d)Vn(j)}, ∀s ∈ S, (1.5)
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where, c(s, d) is the immediate cost of the action d, α is the discount factor, and
p(j|s, d) is the transition probability from state s to state j. This process iterates
until the convergence is met.
Step 3. Choose the near optimal policy π such that:
π(s) = arg min
d∈Ds
{c(s, d) + (1− α)
∑
j∈s
p(j|s, d)Vn(j)}, ∀s ∈ S. (1.6)
The optimal policies minimize/maximize the total expected cost/reward while avoiding the
cancer incidences and death.
1.3.3 A Robust MDP Model to Find Optimal Cancer Prevention Strategies
Given Uncertainties in Transition Probabilities
In Chapter 4, performance of the MDP model under transition probability estimation
errors was studied using a robust Markov decision process (RMDP) framework. A max-min
model was used to obtain robust optimal intervention strategies in the presence of such es-
timation errors as described below.
∏
ps,Ds
:= max
p∈Ps
min
d∈Ds
c(p, d), ∀s ∈ S. (1.7)
This RMDP model is solved using a robust dynamic programming algorithm proposed in [17].
The robust dynamic programming algorithm is based on the steps described next.
Step 1. Set iteration n = 1 and value of state s, Vn(s) > 0 ∀s ∈ S.
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Step 2. For all states, s ∈ S, and action, d ∈ D, solve the inner-problem:
σP ds (Vnj) = maxP
T .Vnj,
P ≥ 0, P.1 = 1, ΣF (s, j) log p(s, j) ≥ β,
where, P is the column vector of transition probabilities, Vnj is the column vector
of the next states values, F (s, j) is the frequency of visits from state s to state j,
p(s, j) is the transition probability from state s to state j, and β is the measure of
uncertainty.
Step 3. For all state, s ∈ S, and action, d ∈ D, update the value function by:
Vn+1(s) = min
d∈Ds
{
c(s, d) + (1− α)σP ds (Vn)
}
.
This process iterates until the convergence is met.
Step 4. Choose the near optimal policy π such that:
π(s) = arg min
d∈Ds
{
c(s, d) + (1− α)σP ds (Vn)
}
Robust MDP model solves a a two-layer optimization problem. The inner problem in
Step 2 solves the worst-case nature policy based on a chosen uncertainty level. This is an
optimization problem which can be solved using a bisection algorithm. In step 4, the optimal
policies are chosen to minimize the total expected cost. The more detailed information on
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robust dynamic programming employing a likelihood model can be found in Chapter 4.
The likelihood function, considered in this dissertation for transition probabilities, is both
statistically accurate and numerically tractable [39].
13
CHAPTER 2: PERFORMANCE OF MACHINE LEARNING MODELS IN
PREDICTING PRESENCE OF BRCA MUTATIONS
2.1 Abstract
Accurate prediction of the presence of a BRCA mutation is important as it signiﬁcantly
increases the probability of developing breast and/or ovarian cancers. Existing Mendelian
and empirical prediction models may lack satisfactory predictive power. Inclusion of more
diverse and/or comprehensive medical and/or family history data may improve performance
of BRCA prediction models. A recent study, the American BRCA Outcomes and Utiliza-
tion of Testing (ABOUT), collected data from a consecutive series of 11,136 individuals
requesting BRCA testing through a national commercial health insurer. In this chapter,
the ABOUT study dataset is used to examine the power of machine learning models for
predicting presence of BRCA mutations. Though machine learning models have received
much attention in medical decision making in recent years, they have not been applied to
the BRCA prediction problem. In this chapter, the performances of the selected machine
learning methods are compared with those from the Mendelian and empirical models widely
used by genetic counselors.
Data from the ABOUT study contains variables that are not incorporated into existing
predictive models. However, it presents some challenges such as class imbalance (with only
9% positive test results) and missing information. To overcome imbalance, parameters of the
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models were tuned by using diﬀerent class weights and misclassiﬁcation costs. For missing
values, a median/mode imputation method was implemented. Among many machine learn-
ing classiﬁers that have been presented in the literature, gradient boosting model (GBM),
random forest (RF), support vector machines (SVM), and regularized logistic regression
(RLR) were chosen as, some of the recent comparative studies have found these methods
to have relatively better predictive power. For performance evaluation, cross-validation and
measurement criteria like the area under the receiver operating characteristic curve (AUC),
Matthews correlation coeﬃcient (Phi coeﬃcient), F-measure, and the area under precision-
recall plots were used. The performances of the selected machine learning methods were
assessed on the ABOUT dataset.
The results show that the GBM outperforms other machine learning methods (SVM,
RF, and RLR). Among the currently used clinical models, performance of IBIS is quite
comparable to that of GBM. The values of Matthews correlation coeﬃcient, F-measure,
AUC, and area under the precision-recall curve for GBM are 0.34, 0.41, 0.76, and 0.29,
respectively, and for IBIS are 0.34, 0.39, 0.71, and 0.3, respectively. Family history of BRCA
test results collected in the ABOUT study, made a signiﬁcant diﬀerence in the performance
of the machine learning models. The performances of the models were assessed again by
excluding this information from the features of the data. The performances of all models
(with a few exceptions for Myriad) were decreased.
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There is signiﬁcant room for further improvement in the performance of the BRCA
prediction models. Experimental results lead us to believe that current data are perhaps
missing some of the critical features, which can raise the performance to an acceptable level.
2.2 Introduction
BRCA1 and BRCA2 are gene mutations that drastically increase the chances (up to 20-
fold) of developing breast and ovarian cancers for women. A genetic test can detect BRCA1/2
mutations. These gene mutations occur in one for every 400 in the general population other
than Ashkenazi Jewish ethnicity for whom it is one in every 50. However, BRCA mutation is
present in most patients with hereditary breast and/or ovarian cancers. It is common practice
for the physicians to use the rules developed by the National Cancer Comprehensive Network
to determine if a BRCA testing is necessary. However, data from the Myriad laboratory
(the only provider of the BRCA test until 2013) shows that over 70% of those tested are
negative [1]. The high cost of the test and the associated psychological distress warrant a
more accurate approach to determining who should be tested.
Existing models in the open literature for predicting presence of BRCA mutation fall
under two main categories: empirical and Mendelian. The empirical models use stratiﬁcation
by family or personal history, for example, Myriad tables [1]. Whereas, Mendelian models
use statistical predictive tools such as Bayesian statistics. Examples include BRCAPRO [40]
and IBIS [41]. Mendelian models generally outperform empirical models since they take
into account more detailed history of BRCA mutations and cancers in the pedigree, un-
like empirical models. Mendelian models use assumptions about genetic parameters such as
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prevalence of BRCA mutations in diﬀerent ethnicities and races, along with Mendelian rules
of gene transmission. However, accurate estimation of the prior probabilities for the pa-
rameters presents a limitation for these models. For example, the true prevalence of BRCA
mutations is often underestimated due to the shortcomings of genetic testing [8]. Accuracy
of the existing Mendelian models suﬀer from a lack of comprehensive consideration of fac-
tors, including race, ethnicity, history of some other types of cancer, previous prophylactic
surgeries, and possibility of mutation transmission through the male members of family [42].
Furthermore, most Mendelian models were developed using limited data from academic re-
cruitment studies, and their performances have not yet been fully studied in a wider general
population.
In this chapter a more accurate prediction method for BRCA mutations is proposed
using a machine learning model (classiﬁer), that is free of prior knowledge/assumptions.
The machine learning models considered in this dissertation are: gradient boosting model
(GBM), random forest (RF), support vector machines (SVM), and regularized logistic re-
gression (RLR). Though the literature on machine learning presents numerous classiﬁcation
methods, prior comparative studies have suggested that SVM, RF, and GBM tend to per-
form better [30] [43]. The RLR was included in the study, since logistic regression is used
commonly in medical decision making [44]. The chosen machine learning classiﬁers make
use of the expanded family history of other types of cancers besides breast and ovarian,
such as prostate, and pancreatic cancers, for up to third degree relatives in the family. The
ABOUT survey data presented some challenges such as missing values and class imbalance.
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These issues were addressed by using median/mode imputation (for missing values) and by
tuning the parameters of models such as class weights and class costs (for imbalance). Other
balancing approaches that are examined include SMOTE [45] and propensity scores [46].
The classiﬁers were tested for various performance measures, including area under the ROC
curve (AUC), the area under the precision-recall plot (AUPR), and Matthews correlation
coeﬃcient (MCC). MCC ranges between -1 and 1, where 1 indicates perfect correlation be-
tween the actual outcome and predicted results (i.e., positive or negative), 0 indicates a
random prediction, and -1 shows a negative correlation [47]. The results from the machine
learning methods were compared with those from well-known currently used clinical models,
including BRCAPRO, IBIS, and Myriad.
2.3 Methodology
In this section, ﬁrst the ABOUT data set is introduced. Thereafter, the author discusses
about the steps for data cleaning and preparation, followed by an outline of the various
machine learning models that were implemented.
2.3.1 Data Set
The data from ABOUT study is the ﬁrst nation-wide patient-reported dataset that
includes individuals who had been approved for BRCA testing through one of the largest
health insurance company in the U.S. from December, 2011 until December, 2012. A total
of 11,136 individuals received a questionnaire (by mail, online, or telephone). The ques-
tionnaire is designed to investigate participant’s BRCA test outcome, personal medical and
surgical history (e.g., breast biopsy and bilateral mastectomy), demographics (age, race and
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ethnicity), and family history of cancer (up to third degree relatives, maternal and paternal)
including type(s) of cancer, age at diagnosis, and BRCA test results. Among this population
study, 3931 individuals responded to the questionnaire and signed the consent form to use
their data in the study [11] [48]. Aside from the ABOUT survey data, provider-reported
information about each participant’s medical and family history of cancers were made avail-
able for this research. Some of the information (e.g., history of having triple negative breast
cancer) was used to augment participant data. In this study, only women with a risk of
having BRCA mutations were considered. Hence, 73 male respondents were excluded. Also,
16 other participants whose responses to the questionnaire were 90% or more incomplete
were eliminated from the dataset.
2.3.2 Data Cleaning and Preparation
The ABOUT survey study comprises a high dimensional data set with several hundred
features. In order to apply a variety of classiﬁer models, the data needed to be cleaned
and prepared. Examples of cleaning include converting descriptive information into cate-
gorical variables and gathering additional information through follow up. Data preparation
comprised imputing missing values, creating new derived variables, and dealing with class
imbalance. Handling missing information is essential for survey data analysis. In this chap-
ter, some of the missing information was retrieved by following up with the participants via
email and phone. However, assumptions were made when follow up was not successful. For
example, when needed, missing data were replaced by median/mode values of those vari-
ables. A critical challenge with the ABOUT data arose from the outcome imbalance with
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only 9% positive BRCA test results. To account for the imbalance, some parameters, such
as cost and class weights, were tuned while applying some of the classiﬁers.
Some derived variables were also created. For example, dummy variables were deﬁned
for breast cancer diagnosed before age 45 and before age 50, respectively. Other derived
variables included a number of ﬁrst, ﬁrst and second, ﬁrst and second and third degree
maternal relatives or (separately) paternal relatives with combinations of breast, ovarian,
prostate, and pancreatic cancers. The number of maternal or (separately) paternal male
relatives with breast cancer was also considered. Age at cancer diagnosis was categorized in
5-year intervals. Separate variables were then considered for the number of ﬁrst, ﬁrst and
second, ﬁrst and second and third degree maternal and (separately) paternal relatives with
an incidence of one or more cancers in those age intervals. All combined, the prepared data
set had a total of 802 variables either original (from the questionnaire) or derived variables.
2.3.3 Statistical and Machine Learning Models
The large number of features and the nature of the problem presents challenges, in-
cluding correlations between the variables, missing values, and class imbalance. Some of the
machine learning methods are well known to overcome these challenges [49]. Gradient boost-
ing model (GBM) can, for example, handle interactions among variables, select important
features, and deal with outliers and missing data. These attributes make GBM an attractive
choice for the BRCA prediction problem.
For the purpose of performance comparison, some of the well known Mendelian and
empirical models, including BRCAPRO, IBIS, and Myriad prevalence tables are used.
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2.3.3.1 Machine Learning Models
Gradient Boosting model (GBM) is a non-parametric tool that iteratively combines
many weak classiﬁers that by themselves perform slightly better than chance, to build a
strong classiﬁer capable of generating class probabilities. Gradient boosting model (GBM)
is a special case of boosting algorithms. At each iteration, GBM builds a new weak model
based on the error observed from the whole ensemble models. The ﬂexibility of GBMs in
dealing with missing values, correlation, and imbalance makes them a good ﬁt for a variety of
classiﬁcation problems [50]. The GBM method was implemented using the ‘dismo’ package
in R [51].
Random forest (RF) is an ensemble method that uses many independent decision trees
for classiﬁcation. Each tree in random forest is trained on a bootstrap sample of training
data using a set of randomly selected features. After a large number of trees have been
built, each tree votes for the majority class. Then the votes are used collectively in making
decision rules [26]. To implement this method, the ‘randomForest’ package in R [52] was
used. Sample sizes and class weights were tuned to deal with the data imbalance.
Support vector machines (SVM) is a semi-parametric technique developed based on the
assumption of linearly separable classes [53]. SVM creates a classiﬁcation based on a linear
combination of the features. It generates weights for covariance based on a transformation of
the feature space and then tries to ﬁnd the best hyperplane that separates the classes. This
method is designed for high dimensional data and no assumption is necessary for parametric
relationship between the model predictors and outcome. To implement SVM, the ‘e1071’
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package in R [54] was used. Class weights and cost parameters were tuned to deal with the
data imbalance issue.
Logistic regression has been used widely for the classiﬁcation problems [44]. Regu-
larization is required for cases where a large number of parameters need to be learned.
L1-regularized logistic regression has been shown to have good generalization performance
in the presence of many irrelevant features [38]. Because of the L1-penalty, the RLR per-
forms both continuous shrinkage and automatic variable selection [55]. For implementing
this method, the ‘glmnet’ package in R [56] [57] was used.
2.3.3.2 State of the Art BRCA Mutation Likelihood Estimators
Myriad mutation prevalence tables [5] present prior probabilities of having a BRCA
mutation estimated using ten characteristics of an individual related to age, ethnicity, and
family history. The available estimates [5], were obtained by ﬁtting a logistic regression on
samples drawn from over 10,000 individuals in Myriads database [58] [59]. It should be noted
that Myriad tables consider family history of ovarian cancer and breast cancer only if it was
diagnosed before age 50 and these tables have not been updated for several years.
BRCAPRO developed by Parmigiani et al. [6] [60] is a Mendelian model with a Bayesian
approach. It uses published BRCA1 and BRCA2 mutation frequencies and cancer speciﬁc
penetrances to implement Bayesian updating and determine the likelihood of mutation in the
pedigree [9]. A ‘BayesMendel’ package in R [61] is used, which applies the peeling algorithm
for analysis of pedigree data in [62]. Several assumptions were made for implementing this
model. For instance, if the age of oophorectomy or mastectomy was missing, assumption is
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that it was done either at age 40 or at age 60. If the age at second reported breast cancer was
missing, it was assumed to be the age of the ﬁrst breast cancer plus ﬁve years. BRCAPRO’s
query for family member’s history of oophorectomy or mastectomy was ignored when such
data was not available. Also, when unavailable, marker testing for ER, CK14, CK56, PR,
and HER2 inputs were ignored. However, if a participant had a triple negative breast cancer,
ER, PR, and HER2 were set to be negatives.
IBIS model developed by Tyrer et al. [7] was the ﬁrst Mendelian model that utilizes
information on endogenous estrogen exposure and history of benign disease using a segrega-
tion analysis [63]. IBIS considers information on personal risk factors, BRCA genes, and a
hypothetical low penetrance gene carried by 21% of the population [7]. The risk of breast
cancer by age 70 for carriers of the hypothetical gene is estimated to be 24% compared to
12% in the general population. IBIS also considers environmental factors such as parity and
hormonal factors. Version 6 of the IBIS model [41] was used in this dissertation. In applying
the model, the following assumptions were made: a participant is menopausal if she is over
50, premenopausal if less than 45, and perimenopausal between 45 and 50. Hormonal use
was ignored due to lack of data. If the age of cancer occurrence was missing for any family
member, it was assumed to be either 40 or 60.
2.4 Results
In this section, ﬁrst, four machine learning models are developed using the ABOUT
study dataset. Thereafter, the performances of these models are compared with those from
the existing Mendelian and empirical models. The eﬃcacy of the two well-known data bal-
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ancing methods: synthetic minority over-sampling technique (SMOTE) [45] and propensity
matching score [64] are then tested. For model building and testing, data from 2997 ques-
tionnaires of participants with positive or negative results is considered. The responses with
either missing or unknown signiﬁcance are excluded. Finally, the performance analysis of
the models is examined by excluding a critical feature (family history of BRCA test result)
from the data.
The data was ﬁrst divided into training and testing data sets containing 70% and 30%
of the dataset, respectively. Both data sets were assigned equal proportion of negative to
positive results. This was accomplished using ‘caret’ package in R [65]. Then the variables
with near zero variance were removed. This eliminated 139 of the 802 features of the dataset.
A 10-fold cross-validation was used for tuning the parameters of the models on the training
set. In the rest of this paragraph, tuning of the parameters is explained.
For GBM, there are 5 parameters to tune: loss function distribution, subsampling
rate (bag fraction), learning rate (shrinkage), number of trees, and interaction depth. A
Bernoulli distribution with a bag fraction of 0.5 was used as recommended in the literature
for classiﬁcation problems [51]. To ﬁnd the number of trees needed, portioning algorithm is
used with 10-fold cross-validation using ‘dismo’ package in R [51]. The learning parameter
was set to 0.01 and the interaction depth was tuned by dividing the data into two sets:
training and testing. The parameters for GBM was chosen so as to minimize the area under
the ROC curve (AUC).
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For RF, two parameters need to be tuned: the number of trees and the number of
features needed to grow each tree. The ‘caret’ package in R was used for this purpose.
Sampling by strata was used, i.e., within each class sample size is equal to the number of
elements in the class with less frequency. Diﬀerent estimates for the number of trees was
used in the range [500, 1000, 2000, 3000, and 4000].
For implementing SVM, ‘e1071’ package in R [54] was used. The two parameters need
to be tuned are sigma and cost of misclassiﬁcation for the minority class. A radial kernel
and a grid search method to tune the parameters were selected. For implementing RLR no
parameter tuning is needed. The ‘glmnet’ package in R [56] with a 5-fold cross-validation
was used.
Table 1 presents the sensitivity and speciﬁcity at optimal cut-oﬀ points of the machine
learning models obtained using the training data set. Among the models, GBM oﬀers the best
performance with highest sensitivity 0.71 and second highest speciﬁcity of 0.76 (compared to
0.77 for RLR) at the cut-oﬀ point of 0.07. GBM selects 160 out of 783 features as inﬂuential
variables.
Table 5 presents a summary of the top inﬂuential features for GBM. The pie chart
in Figure 3 shows the aggregate percentage impact of the inﬂuential features in diﬀerent
categories: BRCA test results, personal information, hormonal factors, personal cancer in-
formation, and family history of cancers on both maternal and paternal sides. The most
inﬂuential feature (with a 35% impact) is the family BRCA test results. Features related to
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maternal and paternal family history of cancers (including breast, ovarian, pancreatic, and
prostate cancers) have 24% and 19% impact, respectively.
Table 5 organizes the set of top inﬂuential features within each category. Every feature
is provided with its percentage of inﬂuence, and the top ten features are identiﬁed with
asterisks. In Table 5 the two most inﬂuential features for family history of cancer are:
incidence of breast, ovarian, pancreatic, and prostate cancers in the 1st, 2nd, and 3rd degree
relatives (including the proband) before age 60 and breast cancer incidence in the ﬁrst degree
relative before age 45.
The performances of the machine learning models were then compared with those from
BRCAPRO, IBIS, and Myriad. The models were applied to the testing data set and the
following performance measures for comparison were used: AUC, AUPR, F-measure, and
MCC. The results are presented in Table 2. Sensitivity- speciﬁcity plots are shown in Figure
1. GBM achieves the highest AUC of 0.76 followed by 0.74 for RF and 0.72 for RLR. IBIS
and GBM have the highest Matthews correlation coeﬃcient (MCC) of 0.34. GBM and IBIS
have the two highest F-measures of 0.41 and 0.39, respectively. GBM and RLR achieve the
highest area under the precision-recall (AUPR) graph of 0.29.
Table 4 shows the MCC scores obtained by applying two of the balancing methods:
synthetic minority over-sampling technique (SMOTE) [45] and propensity matching score
[64]. A 10-fold cross-validation was used on the training set in obtaining the results in Table
4. As the results indicate, applying the balancing methods in this context does not improve
the prediction performance of the machine learning models signiﬁcantly.
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The analyses included data both from those who had a known family mutation as
well as those who were the ﬁrst being tested in the family (no a priori knowledge of family
mutation). It is well known that the knowledge of BRCA test results in the pedigree has
signiﬁcant inﬂuence on the BRCA test outcome. Hence, the data set was further reduced
by excluding the participants with known family BRCA test result(s), and the performance
assessment of the prediction models were repeated. With this exclusion criteria, the data
imbalance increased further to only 5% positive.
Table 3 shows the performance of the models when family history of BRCA testing is
excluded from the dataset. Performance of all methods (with a few exceptions for Myriad)
decreases compared to those presented in Table 2. This reduction is expected as all the
models (except Myriad) make use of the information on BRCA test results in the pedigree;
recall that in GBM, it accounted for 35% of the prognostic inﬂuence (see Figure 3). IBIS
performs better than all other models. Among the machine learning models, GBM performs
better. In the absence of family BRCA history, for GBM, paternal family history of cancer
accounts for 48% of the prognostic inﬂuence. Other inﬂuential factors are maternal family
history of cancer (23%), personal cancer history (12%), personal information (such as age,
race, and history of prophylactic surgeries) (11%), and hormonal factors (6%). Figure 2 shows
the sensitivity-speciﬁcity plots for the top four models. The data balancing methods were
also implemented in this analysis. Like before, balancing does not improve the performance
of the models.
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2.5 Conclusions
It is estimated that up to 1 million people in the United States carry BRCA gene
mutations. The U.S. Preventive Services Task Force (USPSTF) recommends that women
with family history associated with an increased risk of BRCA mutations be referred for ge-
netic counseling and consideration of BRCA testing. USPSTF also advises against referring
individuals with low risk of hereditary breast and/or ovarian cancer for BRCA testing to
avoid potential harm [66] [67]. Hence, it is imperative to have accurate models to predict
the likelihood of having a BRCA mutation.
The two main categories of available mutation prediction tools are empirical and
Mendelian models. Empirical models such as Myriad tables are easy to use and do not
require computer support, but consider only a subset of relevant characteristics. Mendelian
models, such as BRCAPRO and IBIS, outperform the empirical models. However, they
require input of personal and family history via a computer program and are prone to esti-
mation errors of certain parameters such as penetrance and allele frequencies [9]. A limitation
of all empirical and Mendelian models is that they do not fully consider information on other
types of cancers such as pancreatic and prostate cancer, which have been linked with having
a BRCA mutation [68]. Finally, the data used in developing the models referred here (Myr-
iad, BRCAPRO, and IBIS) were obtained from women with cancer. Therefore, applicability
of these models for cancer-free women in the general population is unknown [66].
In this chapter, a set of machine learning based BRCA prediction models were built
that beneﬁted from a recent data collected through a study conducted on a national sample of
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commercially insured individuals undergoing BRCA testing [11]. In this study, participants
provided extensive family cancer history information. The machine learning models that were
examined here are gradient boosting model (GBM), random forest, support vector machines,
and regularized logistic regression. Among these, GBM attained the highest sensitivity and
speciﬁcity. Inﬂuential factors included family history of breast, ovarian, pancreatic and
prostate cancers, as well as male breast cancer.
Results from the machine learning models were compared with those from IBIS, BR-
CAPRO, and Myriad tables, applied to the same dataset. All the models performed signif-
icantly better than chance in discriminating between carriers and non-carriers. Among all
the models, GBM had the highest area under the ROC curve. Because this questionnaire
data set was imbalanced with only 9% positive BRCA test results, the model performances
were assessed using the Matthews correlation coeﬃcient (MCC). MCC performance of IBIS
and GBM were comparable and were better than all other models. Though all the models
performed signiﬁcantly better than chance, their MCC values were less than 0.4, which is
considered a moderate level of performance. Following the recommendations in the literature
on imbalanced dataset [45] [64], two of the data balancing methods, SMOTE and propensity
score, were used. These techniques, however, did not signiﬁcantly improve the MCC scores
of the models. Since knowledge of the BRCA test results in the pedigree has a signiﬁcant
inﬂuence on the BRCA prediction outcome, the models were tested on the data contain-
ing people with no known BRCA history. Models performed lower, suggesting the need for
identiﬁcation of additional features to improve BRCA prediction power.
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The study was limited by missing information necessitating assumptions. Nevertheless,
the study suggests that the inclusion of additional personal and family cancer history features
could improve the BRCA prediction accuracy. Future studies might explore incorporation of
other features such as tumor type (e.g., estrogen receptor/progesterone receptor and HER2
status) [10]. Also, further research to develop new methods of class balancing could be
beneﬁcial. Finally, evaluation of the usability of the BRCA prediction models in diﬀerent
population settings needs to be done before recommending their routine use [10]. In the
end, the IBIS model appears to have reasonable performance characteristics when tested in
a recent population of commercially insured individuals undergoing BRCA testing. Given
the limitations of this study, performances of the machine learning models do not show a
signiﬁcant improvement over the existing models.
Table 1: Sensitivity and speciﬁcity of machine learning models on training data set
Model Sensitivity Speciﬁcity Cut-oﬀ
GBM 0.71 0.76 0.07
RF 0.64 0.72 0.1
SVM 0.64 0.69 0.08
RLR 0.64 0.77 0.07
Table 2: Performance of machine learning, Mendelian, and empirical models on the test set
Model Category Model MCC AUC F-measure AUPR
Machine learning Models
GBM 0.34 0.76 0.41 0.29
RF 0.32 0.74 0.38 0.25
RLR 0.32 0.72 0.38 0.29
SVM 0.3 0.68 0.34 0.23
Mendelian models
BRCAPRO 0.25 0.7 0.3 0.18
IBIS 0.34 0.71 0.39 0.3
Empirical model Myriad 0.2 0.57 0.26 0.15
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Figure 1: Sensitivity-speciﬁcity plot
Table 3: Performance of machine learning, Mendelian, and empirical models on the test set
excluding family history of BRCA test
Model Category Model MCC AUC F-measure AUPR
Machine learning models
GBM 0.18 0.63 0.29 0.1
RF 0.14 0.61 0.22 0.09
RLR 0.1 0.52 0.13 0.07
SVM 0.14 0.55 0.26 0.08
Mendelian models
BRCAPRO 0.18 0.66 0.26 0.12
IBIS 0.22 0.65 0.39 0.14
Empirical model Myriad 0.18 0.63 0.29 0.12
Table 4: Performance of machine learning models after applying balancing methods
Model MCC-propensity MCC-SMOTE
GBM 0.27 0.3
RF 0.31 0.34
SVM 0.21 0.24
RLR 0.3 0.3
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Figure 2: Sensitivity-speciﬁcity plot after excluding family history of BRCA test
Figure 3: Prognostic factors and their relative inﬂuence in the GBM model
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Table 5: Summary of the top inﬂuential factors and their percentage in the GBM
Personal information
* Age (8%)
* Height and weight (3%)
Race (0.4%)
Ethnicity (0.09%)
Hormonal Factors
* History of Bilateral Mastectomy (2%)
History of bilateral oophorectomy (1%)
Age of ﬁrst pregnancy (1%)
History of abnormal breast biopsy (0.08%)
Age of start of menstrual (0.04%)
Personal cancer information
Age at ﬁrst and second breast cancer (0.09%)
Age and History of ovarian cancer (0.08%)
Having a breast cancer before age 45 (0.03%)
Family history cancer information
BRCA test results from ﬁrst, second, and third degree relatives
* Mother’s BRCA test result (20%)
* Sibling’s BRCA test result (8%)
* Maternal Aunt and uncle’s BRCA test result (3%)
Maternal
* Number of 1st, 2nd, and 3rd degree relatives (including the proband) with breast
and ovarian cancers (6%)
* Number of 1st, 2nd, and 3rd degree relatives (including the proband) with breast,
ovarian and pancreatic cancers (3%)
Number of 1st , 2nd, and 3rd degree relatives (including the proband) relatives
with breast, ovarian, pancreatic, and prostate cancers before age 60 (1%)
Number of 1st degree relatives with breast before age 45 (1%)
Paternal
* Number of 1st, 2nd, and 3rd degree relatives (including the proband) with
ovarian cancer (7%)
* Number of 1st, 2nd, and 3rd degree relatives with breast, ovarian
, and pancreatic cancers (2%)
Number of 1st and 2nd degree relatives with breast cancer before age 45 (0.07%)
Number of 1st, 2nd, and 3rd degree relatives with breast, ovarian, pancreatic, and
prostate cancers before age 60 (0.03%)
* represents the top 10 inﬂuential features in the GBM model
33
CHAPTER 3: A MDP MODEL FOR BREAST AND OVARIAN CANCER
INTERVENTION STRATEGIES FOR BRCA1/2 MUTATION CARRIERS
3.1 Abstract
This chapter presents an optimization model that is used to ﬁnd the cost-optimal and
quality-adjusted life year-optimal (QALYs-optimal) intervention strategies for women with
BRCA1/2 mutation for ages between 30 to 65. The state of a carrier is deﬁned by her
age, health status, and prior intervention actions. Preventive actions considered diﬀer in
their costs, major side eﬀects and their cancer prevention abilities. Eﬀectiveness of these
actions also depends on the age when they are taken. The surgical actions considered
are prophylactic oophorectomy for removing both ovaries, and prophylactic mastectomy
for removal of both breasts. Both of these surgical actions cause major side eﬀects. For
example, prophylactic oophorectomy increases the risk of heart diseases and osteoporosis.
All these considerations make the task of ﬁnding optimal intervention strategies a complex
decision making problem. At each year starting from age 30, a mutation carrier can make
a decision as to whether or not to adopt a screening action. Due to the limitations of
data on transition probabilities, the surgical options are considered to be available only at
ages 30, 40, and 50. It is assumed that the state of a BRCA carrier at each year depends
only on the state of that person a year before. Hence, the intervention decision making
problem is modeled as a Markov decision process. The MDP is solved using a value iteration
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algorithm. The existing models used in the literature for recommending preventive actions
are simulation-based models, which are capable of evaluating a set of policies. A MDP
however, is an optimization model that minimizes the total expected cost or maximizes
the total expected reward by considering all the possible choices of actions. Details of the
MDP model are presented in a recently published paper, A MDP model for breast and
ovarian cancer intervention strategies fro BRCA1/2 mutation carriers, which can be found
in Appendix B. The optimal preventive intervention actions based on cost and QALYs
for BRCA1 and BRCA2 mutation carriers suggested by the MDP models can be used as
guidelines by both policy makers and individuals.
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CHAPTER 4: A ROBUST MDP MODEL UNDER TRANSITION
PROBABILITY UNCERTAINTIES FOR BRCA1/2 MUTATION CARRIERS
4.1 Abstract
The Markov decision process (MDP) model, presented in Chapter 3, ﬁnds the optimal
intervention actions for preventing breast and ovarian cancers for BRCA mutation carriers
based on cost or quality-adjusted life years (QALYs). One of the key drivers of the MDP
model is transition probabilities. These probabilities were derived from diﬀerent data sources
and simulation studies. Therefore, these probabilities are prone to estimation errors. In this
chapter, a robust MDP model (RMDP) capable of dealing with such uncertainty is developed.
The robust intervention actions derived from RMDP are presented and compared with those
from the MDP model.
4.2 Introduction
The transition probabilities are one of the most important elements of a MDP model.
These probabilities explain the stochastic nature of changes in a carrier’s health status over
time under various interventions. Estimation errors in transition probabilities may thus
negatively inﬂuence intervention policies obtained from the MDP model. As the transition
probabilities were obtained from diﬀerent public data sources and openly available literature,
it was not possible to ascertain the nature of these errors. However, it is essential to develop
intervention strategies that are robust to such estimation errors. To accomplish this goal, a
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robust Markov decision process model (RMDP) was formulated, from which robust policies
were obtained. The RMDP model attempts to optimize the decision criteria assuming that
the nature is playing the worst-case scenario. Thus, the RMDP model provides policies
that are particularly suited for mutation carriers who are at higher risks of having the worst
outcome.
Three diﬀerent approaches have been presented to the literature that deﬁne uncer-
tainty regions for transition probabilities: a Bayesian approach, a polytopes approach, and
a statistical likelihood model [17]. The Bayesian approach assumes knowledge of the prior
transition probability distributions. Prior probabilities, however, are not always available.
The polytopes or interval approach considers uncertainty in a given set. This kind of ap-
proach often results in very conservative solutions which may not be statistically accurate.
Statistical likelihood models, in most cases, are selected to avoid estimation bias and overly
conservative robust policies [17]. The application of the RMDP in medical literature is new
but growing. For example, it has been applied for evaluating cost-eﬀectiveness of the fecal
immunochemical test screening for colorectal cancer [15]. RMDP has also been used to ﬁnd
optimized medical treatment decisions for patients with type 2 diabetes [69].
This dissertation considers a likelihood statistical model for transition probability un-
certainties. A robust dynamic programming approach is used to solve the cost-optimal and
QALYs-optimal RMDP models. The formulation of the RMDP is presented next, followed
by the results and discussions.
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4.3 A RMDP Model Formulation for Finding Optimal Intervention Strategies
for BRCA1/2 Mutation Carriers
An RMDP model is built for BRCA1/2 mutation carriers between ages 30 to 65. Model
notations used in this section are the same as in Chapter 3. It is assumed that a mutation
carrier chooses a preventive action at the beginning of each year. The state of a BRCA
mutation carrier, s ∈ S, is deﬁned by her age (a), health status (h), and history of prior
intervention actions (i). Intervention actions, d ∈ Ds, are considered to be screening and
surgical actions, where Ds denotes the set of actions available in state s. Screening actions
are made available yearly and surgical options are made available only at ages 30, 40, and
50. The transition probabilities from state s and action d under uncertainty, p ∈ P ds , are
assumed to follow a likelihood model by considering the number of times a state is visited
under a speciﬁed action [70]. A cost-RMDP model objective can be deﬁned as:
min
d∈D
max
p∈P
C(d, p), (4.1)
where optimal policies minimize the total expected cost, C(d, p), under the worst-case sce-
nario.
This problem can be solved via a robust dynamic programming algorithm as discussed
in [17]. Let c(s, d) be the cost of action d in state s, α be the discount factor, and σP ds (V (n+1)
deﬁnes the worst-case future value. The value of state s in iteration n can be deﬁned as:
Vn(s) = min
d∈Ds
{
c(s, d) + (1− α)σP ds (V (n+ 1))
}
, ∀s ∈ S. (4.2a)
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The optimal policy, π∗n(s), for state s in iteration n is obtained by:
π∗n(s) = arg min
d∈Ds
{
c(s, d) + (1− α)σP ds (V (n+ 1))
}
, ∀s ∈ S. (4.2b)
In Equation 4.2a, the inner optimization problem presented by σP ds (V (n+1)) has been solved
via a bisection algorithm, as explained in the next section.
4.3.1 A Statistical Likelihood Uncertainty Model
The uncertainty region deﬁnition for transition probabilities plays a major role in
tractability and conservativeness of the derived policies [69]. Likelihood-based models are
considered to be statistically more accurate and less conservative while computationally
tractable as discussed in [20]. This uncertainty model is described as follows.
Let Nsj denotes the frequency of visits from state s to state j and the transition
probability deﬁnes by psj, the log-likelihood model, L(P ), for this transition given a Dirichlet
distribution can be deﬁned as:
L(P ) =
∑
s,j
log(psj)Nsj, (4.3)
where,
psj ≥ 0 ∀s, j ∈ S,
∑
j
psj = 1 ∀s ∈ S.
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The maximum likelihood βmax is obtained by replacing psj in Equation 4.3 by
psj = Nsj/
∑
k∈S
Nsk. (4.4)
For an RMDP model with a likelihood uncertainty level, β < βmax, the inner optimiza-
tion problem can be formulated by maximizing the future value as:
max
p∈P ds
∑
j∈S
psjV (j) (4.5)
L(P ) =
∑
sj
log(psj)Nsj ≥ βs : psj ≥ 0 ∀s, j ∈ S,
∑
j
psj = 1 ∀s ∈ S,
where
βs = β −
∑
k =s
∑
j
Nkj log(Nkj/
∑
l∈S
Nkl).
A Lagrangian relaxation method can be implemented for solving this maximization
problem. The optimal solution is deﬁned by Lagrangian multipliers λ, μ, and ζ by:
p∗sj =
λNsj
μ− V (j)− ζ(j) . (4.6)
As shown in [17], the optimal value of ζ is zero and λ can be written as a function of the μ
λ(μ) = (
∑
(
Nsj
μ− V (s)))
−1. (4.7)
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Hence, in order to ﬁnd the optimal worst-case scenarios for transition probabilities, the
ﬁrst step is to ﬁnd μ with a bisection algorithm described below.
Step 1. For a selected level of γ: μ− = Vmax and μ+ =
Vmax − exp( β − βmax)V¯
1− exp( β − βmax)
Vmax = max(Vj), V¯s = N
TV , and β =
∑n
j=1Nj log pj − 0.5 ∗ χ2n(n−1),1−γ
Step 2. While |σ′(μ+)− σ′(μ−)| ≤ δ:
(a) μ =
μ+ + μ−
2
(b) compute σ
′
: σ
′
=
∑
j N(j) log
λ(μ)N(j)
μ− V (j) − β
(c) if σ
′ ≥ 0 then μ+ = μ otherwise μ− = μ
(d) go to (a)
4.3.2 Robust Dynamic Programming Algorithm
The robust dynamic programming algorithm in [17] is implemented in this Chapter to
ﬁnd the optimal robust intervention strategies for the RMDP model. The algorithm to solve
the RMDP model with a likelihood uncertainty is described next.
Step 1. Set  ≥ 0, deﬁne V1 ≥ 0 and iteration l = 1
Step 2. Solve the inner problem using the bisection algorithm
σP ds = maxP
TV ∀s ∈ S ∀d ∈ Ds (4.8)
Step 3. For all s ∈ S and d ∈ Ds ﬁnd Vl+1(s) using:
Vl+1(s) = min
d∈Ds
{
c(s, d)+(1− α)σP ds
}
(4.9)
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if |Vl+1 − Vl| < δ go to Step 4; else repeat Step 2, where δ = α/2(1−α) and α is the
discount factor.
Step 4. Find the optimal policy using:
π(s) = arg min
d∈Ds
{
c(s, d)+(1− α)σP ds
}
, s ∈ S (4.10)
In the next section, the results of the RMDP model are presented and compared with
the ones from the MDP model.
4.4 Results
The RMDP model was solved using the robust dynamic programing algorithm. The
algorithm was coded in Java and was implemented using an Intel dual core processor with
16 GB RAM. On average, the RMDP took 5 times more than the MDP model to converge.
To study the eﬀect of estimation errors on transition probabilities of transient states, the
level of uncertainty was altered from 0.1 to 0.5 with an increment of 0.1. Figure 4 displays
one-step transition probability changes under diﬀerent uncertainty levels for a healthy 40
year old BRCA1 mutation carrier who undergone prophylactic mastectomy (PM) and pro-
phylactic oophorectomy (PO) at age 40. At near zero uncertainty, the RMDP transition
probabilities are the same as the MDP. As the level of uncertainty increases, the RMDP
transition probabilities begin to change. The absorbing state of distant breast cancer has
the highest cost (i.e., worst-case scenario). As the level of uncertainty on transition probabil-
ities increases, the probability of ending up in the distant stage of a breast cancer increases
and other probabilities decrease.
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The RMDP model was solved ﬁrst by using the cost criteria. For a BRCA1 mutation
carrier, with increasing the level of uncertainty, the optimal surgical strategies remain the
same, while some screening actions change slightly. This suggests that the MDP model
recommendations are robust to the transition probability estimation errors. Whereas, for a
BRCA2 mutation carrier, after the level of uncertainty increases to more than 10%, some
of the cost-optimal strategies change. The MDP and RMDP with 10% level of uncertainty,
cost-optimal intervention strategies are summarized based on the age of a BRCA2 mutation
carrier and the prior intervention actions in Table 6 and Table 7, respectively. When the
uncertainty level is between 10 to 20 percent, for a healthy 30 year old BRCA2 mutation
carrier, the recommendations from both models are the same. However, for a 40 year old
BRCA2 mutation carriers with no prior intervention histories, the recommendations diﬀer.
For a 40 year old, the MDP model recommends a combination of PM and PO at age 40 as
shown in column one of Table 6. Whereas, the RMDP model suggests PM at age 40 but
delays PO to age 50 (see Table 7). As, the level of uncertainty increases to 30%, in addition
to the previous changes, for a 50 year old with history of PM at age 30, the MDP model
advices undergoing PO at age 50. Whereas, the RMDP model recommends yearly screening
instead of an additional surgery. The screening actions recommended by the RMDP are only
slightly diﬀerent than the ones suggested by the MDP and can be observed from the tables.
The RMDP model was solved again by considering the states’ utilities to ﬁnd the
QALYs-optimal policies. For a BRCA1 mutation carrier, when the uncertainty level is in-
creased to 10%, the recommended actions for a healthy 30 year old with no prior intervention
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action changes. The MDP model suggests PO at age 30 followed by PM at age 50 in Table
V of the Appendix B but, the RMDP model recommends yearly screening before age 40
followed by a combination of PM and PO at age 40. The RMDP QALYs-optimal policies
when the uncertainty level is 10%, are summarized in Table 8. Other strategies remain the
same between the MDP and the RMDP model. When the uncertainty level increases to
30%, the RMDP strategies for a healthy mutation carrier with no prior intervention history
shifts to no surgery before age 50 and only yearly screening. At the age of 50, the RMDP
recommends PM. When the uncertainty reaches 40%, for a healthy mutation carrier with
history of PM at age 30, PO is not recommended and substituted with yearly screening
and other strategies remain the same. For a BRCA2 mutation carrier, after increasing the
uncertainty level to 10%, for a healthy mutation carrier with no prior history, only screening
is recommended (see Table 9). After uncertainty level increases to more than 20% for a
healthy 40 and 50 year old with prior history of PM at 30, no PO is recommended. The
MDP recommended strategies are presented in Table VII of Appendix B.
4.4.1 Assessment of the RMDP Optimal Policies
In this section, some of the RMDP-optimal and MDP-optimal strategies are evaluated
and compared. For this purpose, the BRCA Tool [70] health outcome probabilities by age 70
of the recommended strategies is used, similar to Chapter 3. The optimal strategies of the
MDP and the RMDP with 30% uncertainty level for a healthy 30 year old BRCA1 mutation
carrier with no prior intervention actions are summarized in Table 10. For these optimal
policies, Table 12 displays the health outcome probabilities. For cost-optimal strategies,
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both RMDP and MDP models suggest a combination of PM and PO by age 30. Therefore,
the probabilities reported are the same. However, for QALYs-optimal strategies, the RMDP
model has a lower probability of death from other causes of 11% compared to 13% of the
RMDP model. However, the RMDP model has higher probabilities for breast and ovarian
cancers and lower probability of being healthy. It might be noted that in the RMDP model,
death from other causes has the lowest utility for a person i.e., the worst-case scenario. In
addition, preventive surgeries, PM and PO, increase the chance of death due to other causes
because of their major side eﬀects as explained in Appendix B.
Then, the optimal intervention strategies of MDP and RMDP models are contrasted
for a healthy 40 year old BRCA2 mutation carrier with no prior intervention history as
listed in Table 11. The health outcome probabilities by age 70 are reported in Table 13. For
the cost-optimal strategies, the health outcome probabilities are comparable. However, for
QALYs-optimal strategies, the RMDP model has a lower probability of death from other
causes of 13% compared to 14% of the MDP model. The RMDP model compared to the
MDP model has a higher probability of breast cancer and a lower probability of being healthy
by age 70 (see Table 13).
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Figure 4: Cost-optimal RMDP one-step transition probabilities for a healthy 40 year old
BRCA1 mutation carrier after taking PM+PO-40 action
Table 6: MDP cost-optimal intervention strategies for BRCA2 mutation carriers
Age None PO-30 PM-30 PM+PO-30 PO-40 PM-40 PM+PO-40 PM30+PO-40 PM40+PO30 PO-50 PM-50 PM+PO-50 PM30+PO-50 PM40+PO50 PO30+PM40 PO30+PM50
30 PO NSc NSc NSc
31 Sc NSc NSc NSc
32 Sc NSc NSc NSc
33 Sc NSc NSc NSc
34 Sc NSc NSc NSc
35 Sc NSc NSc NSc
36 Sc NSc NSc NSc
37 Sc NSc NSc NSc
38 Sc NSc NSc NSc
39 Sc NSc NSc NSc
40 PM+PO PM PO NSc Sc NSc Sc Sc NSc
41 Sc NSc NSc NSc Sc NSc Sc Sc NSc
42 Sc NSc NSc NSc Sc NSc Sc Sc NSc
43 Sc NSc NSc NSc Sc NSc Sc Sc NSc
44 Sc NSc NSc NSc Sc NSc Sc Sc NSc
45 Sc NSc NSc NSc Sc NSc Sc Sc NSc
46 Sc Sc NSc NSc Sc NSc Sc Sc NSc
47 Sc Sc NSc NSc Sc NSc Sc Sc NSc
48 Sc Sc NSc NSc Sc NSc Sc Sc NSc
49 Sc Sc NSc NSc Sc NSc Sc Sc NSc
50 PM+PO PM PO NSc PM PO Sc Sc NSc Sc Sc Sc NSc Sc Sc Sc
51 Sc Sc NSc NSc Sc NSc Sc Sc NSc Sc Sc Sc NSc Sc Sc Sc
52 Sc Sc NSc NSc Sc NSc Sc Sc NSc Sc Sc Sc NSc Sc Sc Sc
53 Sc Sc NSc NSc Sc NSc Sc Sc NSc Sc Sc Sc NSc Sc Sc Sc
54 Sc Sc NSc NSc Sc NSc Sc Sc NSc Sc Sc Sc NSc Sc Sc Sc
55 Sc Sc NSc NSc Sc NSc Sc Sc NSc Sc Sc Sc NSc Sc Sc Sc
56 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
57 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
58 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
59 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
60 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
61 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
62 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
63 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
64 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
65 Sc Sc NSc NSc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
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Table 7: RMDP with 10% uncertainty cost-optimal intervention strategies for BRCA2 mu-
tation carriers
Age None PO-30 PM-30 PM+PO-30 PO-40 PM-40 PM+PO-40 PM30+PO-40 PM40+PO30 PO-50 PM-50 PM+PO-50 PM30+PO-50 PM40+PO50 PO30+PM40 PO30+PM50
30 PO NSc NSc NSc
31 Sc NSc NSc NSc
32 Sc NSc NSc NSc
33 Sc NSc NSc NSc
34 Sc NSc NSc NSc
35 Sc NSc NSc NSc
36 Sc Sc NSc NSc
37 Sc Sc NSc NSc
38 Sc Sc NSc NSc
39 Sc Sc NSc NSc
40 PM PM PO NSc Sc Sc Sc Sc NSc
41 Sc Sc NSc NSc Sc Sc Sc Sc NSc
42 Sc Sc NSc NSc Sc Sc Sc Sc NSc
43 Sc Sc NSc NSc Sc Sc Sc Sc NSc
44 Sc Sc NSc NSc Sc Sc Sc Sc NSc
45 Sc Sc NSc NSc Sc Sc Sc Sc NSc
46 Sc Sc NSc NSc Sc Sc Sc Sc NSc
47 Sc Sc NSc NSc Sc Sc Sc Sc NSc
48 Sc Sc NSc NSc Sc Sc Sc Sc NSc
49 Sc Sc NSc NSc Sc Sc Sc Sc NSc
50 PM+PO PM PO NSc PM PO Sc Sc NSc NSc Sc Sc NSc Sc Sc Sc
51 Sc Sc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc NSc Sc Sc Sc
52 Sc Sc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc NSc Sc Sc Sc
53 Sc Sc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc NSc Sc Sc Sc
54 Sc Sc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc NSc Sc Sc Sc
55 Sc Sc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc NSc Sc Sc Sc
56 Sc Sc NSc NSc Sc Sc Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc
57 Sc Sc NSc NSc Sc Sc Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc
58 Sc Sc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
59 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
60 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
61 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
62 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
63 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
64 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
65 Sc Sc Sc NSc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc Sc
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Table 8: RMDP with 10% uncertainty QALYs-optimal intervention strategies for BRCA1
mutation carriers
Age None PO-30 PM-30 PM+PO-30 PO-40 PM-40 PM+PO-40 PM30+PO-40 PM40+PO30 PO-50 PM-50 PM+PO-50 PM30+PO-50 PM40+PO50 PO30+PM40 PO30+PM50
30 Sc NSc Sc Sc
31 Sc NSc Sc Sc
32 Sc NSc Sc Sc
33 Sc NSc Sc Sc
34 Sc NSc Sc Sc
35 Sc NSc Sc Sc
36 Sc NSc Sc Sc
37 Sc NSc Sc Sc
38 Sc NSc Sc Sc
39 Sc NSc Sc Sc
40 PO+PM NSc PO Sc NSc NSc NSc NSc Sc
41 Sc NSc Sc Sc NSc NSc NSc NSc Sc
42 Sc NSc Sc Sc NSc NSc NSc NSc Sc
43 Sc NSc Sc Sc NSc NSc NSc NSc Sc
44 Sc NSc Sc Sc NSc NSc NSc NSc Sc
45 Sc NSc Sc Sc NSc NSc NSc NSc Sc
46 Sc NSc Sc Sc NSc NSc NSc NSc Sc
47 Sc NSc Sc Sc NSc NSc NSc NSc Sc
48 Sc NSc Sc Sc NSc NSc NSc NSc Sc
49 Sc NSc Sc Sc NSc NSc NSc NSc Sc
50 PM PM PO Sc PM NSc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc
51 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc
52 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc
53 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc
54 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc
55 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc NSc NSc Sc Sc
56 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
57 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
58 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
59 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
60 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
61 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
62 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
63 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
64 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
65 Sc NSc Sc Sc NSc NSc NSc NSc Sc Sc Sc Sc Sc Sc Sc Sc
4.5 Conclusions
In this chapter, the MDP model presented in Chapter 3 was extended to a robust
MDP (RMDP) model by considering uncertainty in transition probabilities. MDP models
are powerful decision making tools, but often not used due to their sensitivity to parame-
ter estimation errors [71]. In the open literature, sensitivity analysis was used in Markov
chain models for evaluating the eﬀect of uncertainty on the transition probabilities [13] [14].
The transition probabilities of the MDP model were derived from diﬀerent data sources.
Therefore, to better study the total eﬀect of estimation errors on the outcome policies, a
RMDP framework was used. This model ﬁrst ﬁnds the conﬁdence regions of the transition
probabilities for each state and action, then it optimizes the objective function given the
worst-case scenario using those regions [71]. A likelihood deﬁnition of uncertainty was used
for the RMDP model. The parameters used for this model were the same as in Chapter 3.
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Table 9: RMDP with 10% uncertainty QALYs-optimal intervention strategies for BRCA2
mutation carriers
Age None PO-30 PM-30 PM+PO-30 PO-40 PM-40 PM+PO-40 PM30+PO-40 PM40+PO30 PO-50 PM-50 PM+PO-50 PM30+PO-50 PM40+PO50 PO30+PM40 PO30+PM50
30 Sc Sc NSc NSc
31 Sc Sc NSc NSc
32 Sc Sc NSc NSc
33 Sc Sc NSc NSc
34 Sc Sc NSc NSc
35 Sc Sc NSc NSc
36 Sc Sc NSc NSc
37 Sc Sc NSc NSc
38 Sc Sc NSc NSc
39 Sc Sc NSc NSc
40 Sc Sc PO NSc Sc Sc Sc Sc NSc
41 Sc Sc NSc NSc Sc Sc Sc Sc NSc
42 Sc Sc NSc NSc Sc Sc Sc Sc NSc
43 Sc Sc NSc NSc Sc Sc Sc Sc NSc
44 Sc Sc NSc NSc Sc Sc Sc Sc NSc
45 Sc Sc NSc NSc Sc Sc Sc Sc NSc
46 Sc Sc NSc NSc Sc Sc Sc Sc NSc
47 Sc Sc NSc NSc Sc Sc Sc Sc NSc
48 Sc Sc NSc NSc Sc Sc Sc Sc NSc
49 Sc Sc NSc NSc Sc Sc Sc Sc NSc
50 Sc PM PO NSc PM Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
51 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
52 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
53 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
54 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
55 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
56 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
57 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
58 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
59 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
60 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
61 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
62 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
63 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
64 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
65 Sc Sc NSc NSc Sc Sc Sc Sc NSc Sc Sc NSc NSc NSc NSc NSc
For each experiment, the level of uncertainty was increased by 10%. The cost-optimal and
QALYs-optimal strategies were reported.
First, the cost-optimal policies of the RMDP and the MDP model were compared. For
a BRCA1 mutation carrier, increasing the level of uncertainty does not signiﬁcantly change
the optimal policies. Therefore, the MDP cost-optimal strategies are robust to changes
in transition probabilities. The MDP cost-optimal strategies for a BRCA2 mutation carrier
change slightly after increasing the level of uncertainty to 10%. The strategies recommending
PM do not change. Therefore, for preventing the worst-case scenario, i.e distant breast
cancer, PM is recommended at ages 30, 40, and 50. However, some of the optimal strategies
suggesting PO are delayed.
Then, the QALYs-optimal strategies for BRCA1 and BRCA2 mutation carriers were
contrasted. For the QALYs models, death from other causes has the lowest utility and
hence is considered as the worst-case scenario. In the case of the BRCA1 mutation, the
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RMDP optimal strategies changes after increasing the uncertainty level to 10%. The RMDP
model for a healthy 30 year old recommends only yearly screening from ages 30 to 40 and
delays PO to age 40 and PM to age 50 due to their major side eﬀects. In the case of the
BRCA2 mutation, as the level of uncertainty increases, the surgical strategies change to more
screening actions similar to BRCA1.
The optimal strategies of the MDP and the RMDP model with 30% uncertainty were
selected for a healthy BRCA1 and BRCA2 mutation carriers at ages 30 and 40, respectively.
The outcome of the MDP and the RMDP model, with 30% uncertainty level, were contrasted
based on the health outcome probabilities by age 70 using the BRCA Tool [70]. For the cost-
optimal strategies, the health outcomes for both MDP and the RMDPmodels are similar. For
QALYs-optimal strategies, the RMDP has better outcomes in terms of preventing death from
other causes. However, the MDP-recommended strategies have equal or better outcomes for
other health states compared to the RMDP model.
Limitations of the RMDP models come from the assumptions made by the original
MDP model. For example, surgical actions are still only available at ages 30, 40, and 50.
Some of the other shortcomings emerge from the robust MDP model assumptions. For
example, the uncertainty for diﬀerent states are assumed to be uncoupled, which may cause
the RMDP strategies to be conservative [72]. Finally, reward values used for solving the
MDP models are also prone to estimation errors and can be further considered in the RMDP
model. Given, the limitations of the current RMDP model, there is a further room for future
research.
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Table 10: Comparison of MDP and RMDP optimal strategies for a healthy 30 year old
BRCA1 mutation carrier
Cost-optimal QALYs-optimal
Age MDP RMDP-10% RMDP-30% MDP RMDP-10% RMDP-30%
30 PM+PO PM+PO PM+PO PO Sc Sc
31 NSc NSc NSc NSc Sc Sc
32 NSc NSc NSc NSc Sc Sc
33 NSc NSc NSc NSc Sc Sc
34 NSc NSc NSc NSc Sc Sc
35 NSc NSc NSc NSc Sc Sc
36 NSc NSc NSc NSc Sc Sc
37 NSc NSc NSc NSc Sc Sc
38 NSc NSc NSc NSc Sc Sc
39 NSc NSc NSc NSc Sc Sc
40 NSc NSc NSc NSc PM+PO Sc
41 NSc NSc NSc NSc NSc Sc
42 NSc NSc NSc NSc NSc Sc
43 NSc NSc NSc NSc NSc Sc
44 NSc NSc NSc NSc NSc Sc
45 NSc NSc NSc NSc NSc Sc
46 NSc NSc NSc NSc NSc Sc
47 NSc NSc NSc NSc NSc Sc
48 NSc NSc NSc NSc NSc Sc
49 NSc NSc NSc NSc NSc Sc
50 NSc NSc NSc PM NSc PM
51 NSc NSc NSc Sc NSc Sc
52 NSc NSc NSc Sc NSc Sc
53 NSc NSc NSc Sc NSc Sc
54 NSc NSc NSc Sc NSc Sc
55 NSc NSc NSc Sc NSc Sc
56 NSc NSc NSc Sc NSc Sc
57 NSc NSc Sc Sc NSc Sc
58 NSc NSc Sc Sc NSc Sc
59 NSc NSc Sc Sc NSc Sc
60 NSc NSc Sc Sc NSc Sc
61 NSc NSc Sc Sc NSc Sc
62 NSc NSc Sc Sc NSc Sc
63 NSc NSc Sc Sc NSc Sc
64 NSc NSc Sc Sc NSc Sc
65 NSc NSc Sc Sc NSc Sc
Table 11: Comparison of MDP and RMDP optimal strategies for a healthy 40 year old
BRCA2 mutation carrier
Cost-optimal QALYs-optimal
Age MDP RMDP-30% MDP RMDP-30%
40 PM+PO PM PM Sc
41 Sc Sc Sc Sc
42 Sc Sc Sc Sc
43 Sc Sc Sc Sc
44 Sc Sc Sc Sc
45 Sc Sc Sc Sc
46 Sc Sc Sc Sc
47 Sc Sc Sc Sc
48 Sc Sc Sc Sc
49 Sc Sc Sc Sc
50 Sc PO Sc Sc
51 Sc Sc Sc Sc
52 Sc Sc Sc Sc
53 Sc Sc Sc Sc
54 Sc Sc Sc Sc
55 Sc Sc Sc Sc
56 Sc Sc Sc Sc
57 Sc Sc Sc Sc
58 Sc Sc Sc Sc
59 Sc Sc Sc Sc
60 Sc Sc Sc Sc
61 Sc Sc Sc Sc
62 Sc Sc Sc Sc
63 Sc Sc Sc Sc
64 Sc Sc Sc Sc
65 Sc Sc Sc Sc
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Table 12: Comparison of health outcome probabilities by age 70 for strategies in Table 10
for a healthy 30 year old BRCA1 mutation carrier with no prior intervention history
Outcome measure Cost-Optimal QALYs-Optimal
Model MDP RMDP-30% MDP RMDP-30%
Strategy PM+PO-30 PM+PO-30 PO30+PM50 PM-50
Health Outcome
Death from other causes 0.16 0.16 0.13 0.11
Ovarian cancer 0.07 0.07 0.08 0.3
Breast cancer 0.05 0.05 0.2 0.32
Healthy 0.72 0.72 0.59 0.27
Table 13: Comparison of health outcome probabilities by age 70 for strategies in Table 11
for a healthy 40 year old BRCA2 mutation carrier with no prior intervention history
Outcome measure Cost-Optimal QALYs-Optimal
Model MDP RMDP-30% MDP RMDP-30%
Strategy PM+PO-40 PM40-PO50 PM-40 No surgery
Health Outcome
Death from other causes 0.15 0.14 0.14 0.13
Ovarian cancer 0.03 0.03 0.1 0.1
Breast cancer 0.06 0.07 0.06 0.39
Healthy 0.76 0.76 0.7 0.38
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CHAPTER 5: FINAL REMARKS
In this dissertation, a data-driven decision making platform is developed focusing on
individuals at high risk of getting breast and ovarian cancers due to their BRCA gene mu-
tations. First a likelihood estimation model is built based on a gradient boosting model.
This model is capable of identifying individuals at high risk of having a BRCA mutation
based on their family and personal history of cancers. Then, a Markov decision process
(MDP) model is formulated to help BRCA mutation carriers and their health providers to
ﬁnd eﬀective intervention actions (based on cost or quality-adjusted life years) to prevent
breast and ovarian cancers. Finally, a robust MDP (RMDP) model is presented to study
the sensitivity of MDP optimal strategies under uncertainty. In what follows, I present a
summary of ﬁndings in Chapters 2, 3, and 4 of this dissertation.
In Chapter 2, four machine learning classiﬁers are used to ﬁnd the likelihood of hav-
ing BRCA mutation based on detailed personal and family history of cancer information.
The data used for validation of the models emerges from a recent nation-wide survey study
(ABOUT) of those who requested BRCA genetic testing through one of the commercial
health insurance companies in the United States. This is the ﬁrst study evaluating existing
well-known BRCA risk estimation models using data on general population in the United
States. The models considered were gradient boosting model (GBM), random forest, sup-
port vector machines, and regularized logistic regression. These models are then compared
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and validated using the ABOUT data with some well-known methods in the literature (BR-
CAPRO, IBIS, Myriad prevalence tables). The GBM model outperforms other existing
models as well as other machine learning algorithms based on a selected number of perfor-
mance criteria such as area under the ROC curve and Matthews correlation coeﬃcient. For
the GBM model, history of cancers such as prostate and pancreatic, which were not used in
the previous studies, are associated with having a BRCA mutation. The variable importance
measure in GBM, ﬁnds the history of BRCA testing in the family to be among the most
inﬂuential factors. However, if this variable is removed from the model, the performance of
the machine learning decreases, suggesting the need for additional features. Among the ex-
isting models in the literature, IBIS model has a reasonable performance on the test set. The
limitations of the GBM model come from the assumptions made due to data incompleteness
and imbalance class problems. Features such as estrogen receptor and HER2 status are also
not considered in this model.
A genetic consultant or an individual can use the GBM model presented in Chapter 2
to ﬁnd the likelihood of having the BRCA mutation. If they are at a high risk of having the
mutations, they are referred to do a genetic blood test. For those identiﬁed with positive
mutation results, the next step is to ﬁnd eﬀective intervention actions to prevent breast
and ovarian cancers. The MDP model proposed in Chapter 3 is an attempt to answer this
problem. The state of a BRCA mutation carrier is deﬁned by her age, health status, and
prior intervention action history. Given the set of screening and surgical intervention actions
and cost/utility of these actions in each state, a MDP model is developed. To solve the
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MDP model, a value iteration algorithm is used. This framework extends the Markov chain
simulation models in the literature from evaluation of several eﬀective policies to oﬀering
optimal decision actions. This chapter presents yearly recommendations for BRCA1/2 mu-
tation carriers of ages 30 to 65 with any prior intervention history based on cost/QALYs. The
limitations of the MDP models derive from the assumptions made and the data availability
on the transition probabilities.
Since transition probabilities play an important role in the solution of a MDP model, in
Chapter 4, sensitivity and robustness of the results presented in Chapter 3 are evaluated with
the use of a robust MDP (RMDP) platform. A likelihood statistical deﬁnition of uncertainty
is used for the transition probabilities. The RMDP cost and QALYs optimal intervention
strategies for BRCA1 and BRCA2 mutation carriers are reported and compared with the
MDP model. The strategies from the MDP model are compared with the ones from the
RMDP with respect to health probability outcomes by age 70. The strategies presented by
the RMDP can better help those individuals at a high risk of facing the worst-case scenario.
The limitations of the RMDP model come from the assumptions of the original MDP models
and the RMDP framework as discussed in Chapter 4.
In conclusion, the research presented in this dissertation aims to help individuals and
physicians make more informed medical decisions. The more data becomes available through
studies such as ABOUT, the more accurate models can be built and the more predictive
features can be found to help individuals and their families with diﬃcult and complex medical
decisions.
55
At the end, research on models recommending preventive actions for individuals at
high risk of cancers, such as the MDP and the RMDP models, can save millions of lives and
millions of dollars in medical treatment expenditure.
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Abstract—Purpose: Women with BRCA1/2 mutations have
higher risk for breast and ovarian cancers. Available interven-
tion actions include prophylactic surgeries and breast screening,
which vary signiﬁcantly in cost, cancer prevention, and in result-
ing death from other causes. We present a model designed to yield
optimal intervention strategies for mutation carriers between the
ages of 30 and 65 and any prior intervention history. Methods:
A Markov decision process (MDP) model is developed that con-
siders yearly state transitions for the mutation carriers and state
dependent intervention actions. State is deﬁned as a vector com-
prisingmutation type, health states, prior intervention actions, and
age. A discounted value iteration algorithm is used to obtain opti-
mal strategies from the MDP model using both cost and quality-
adjusted life years (QALYs) as rewards. Results: The results from
MDP model show that for 30-year-old women with BRCA1 mu-
tation and no prior intervention history, the cost-optimal strategy
is a combination of prophylactic mastectomy (PM) and prophy-
lactic oophorectomy (PO) at age 30 with no screening afterwards.
Whereas, the QALYs-optimal strategy suggests PO at age 30 and
PM at age 50 with screening afterwards. For BRCA2 mutation
carriers at age 30, the cost-optimal strategy is PO at age 30, PM
at age 40, and yearly screening only after age 56. Corresponding
QALYs-optimal strategy is PM at age 40 with screening. Strategies
for all other ages (31 to 65) are obtained and presented. It is also
demonstrated that the cost-optimal strategies offer near maximum
survival rate and near minimum cancer incidence rates by age 70,
when compared to other ad hoc strategies.
Index Terms—BRCA1/2 mutations, hereditary breast and ovar-
ian cancer, intervention strategies, Markov decision process
(MDP).
I. INTRODUCTION
I T is estimated that more than 300 000 women in the UnitedStates carry BRCA1 or BRCA2 gene mutations. These car-
riers, who make up 5 to 10% of breast cancer patients, have ﬁve
to 20-fold increased risks of developing breast cancer (56% to
85%) and ovarian cancer (16% to 63%) in their lifetimes [1].
BRCA1/2 mutation carriers may choose to undergo prophylac-
tic mastectomy (PM) and/or prophylactic oophorectomy (PO)
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to dramatically reduce their risks of breast and ovarian can-
cers. PM reduces the relative risk of breast cancer in women
to 0.1, whereas PO offers a relative risk of 0.6 of breast cancer
and 0.04 of ovarian cancer [2]. Most recently, Finch et al. [3]
reported that PO also reduces overall risk of death by age 70
by 77%. Since the mutation carriers are considered as high
risk population, organizations such as American Cancer Society
and National Comprehensive Cancer Network suggest annual
screening with mammography and magnetic resonance imaging
(MRI). MRI offers higher sensitivity in some cases and lower
speciﬁcity when compared tomammography [4]. Therefore, en-
hanced cancer screening beginning at a young age using both
mammography and MRI with the intent of early detection [5]
is considered in this paper. Since the number and type of avail-
able drugs for chemoprevention are limited [6] and studies on
medications, such as tamoxifen and raloxifene, on reduction
of the incidence of invasive breast cancer in BRCA1/2 muta-
tion carriers [7] are limited, we did not consider those in our
model.
Mutation carriers and their physicians often struggle with
formulating an effective intervention strategy. Usual dilemmas
include the choice of preventive surgeries, the age atwhich to un-
dergo a chosen surgery, andwhether or not to screen in any given
year [5], [8]. The choice of intervention actions is guided by the
following: increased survival, reduced incidence of breast and
ovarian cancers, quality-adjusted life years (QALYs), increased
probability of death from other causes, and the costs and other
undesirable consequences of intervention actions and treatment.
Intervention strategies that include prophylactic oophorec-
tomy are in conﬂict with the desire of women to have children
at older ages. Bilateral salpingo–oophoroctomy causes early
menopause, increased heart diseases, higher risk of osteoporo-
sis, and for some women, loss of sexuality and gender identity.
Bilateralmastectomymay have a higher psychological impact as
it affects the body image [9]. As shown in [10], annual screening
with mammography and MRI was linked to the longest quality
adjusted survival for women with BRCA1/2 mutation. How-
ever, it is expensive and often leads to false positives, thereby
increasing anxiety and costs [11].
Finding a good intervention strategy is difﬁcult as the com-
monly considered strategies have not been assessed compar-
atively through randomized trials [5]. Most of the studies in
the literature also do not fully characterized the patient experi-
ence. Moreover, breast cancer inﬂicts a substantial medical and
economic burden to society. Based on the National Cancer Insti-
tute report for 2011–2012, $124.6 billion worth of medical care
2168-2194 © 2014 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission.
See http://www.ieee.org/publications standards/publications/rights/index.html for more information.
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expenditures were made for cancer care in the United States,
of which female breast cancer accounted for $16.5 billion and
ovarian cancer accounted for $5.1 billion [12]. It was estimated
in the American Cancer Society report for 2012 that 39 510
deaths in the U.S. were due to female breast cancer and 15 500
deaths were due to ovarian cancer [12]. It is estimated that a
cost-effective intervention strategy for BRCA1/2 mutation car-
riers may save up to $800 million a year in cancer treatment
costs [13].
Open literature offers simulation driven Markov models ca-
pable of evaluating given ad hoc strategies with regards to cost
and survival. To our knowledge, a model-based tool to select an
optimal intervention strategy from the set of all possible strate-
gies (strategy space) is not available. Such a model requires
the ability to consider the dynamics of variable action choices
in different health states, their impact on health state transition
probabilities, and their expected costs. Our Markov decision
process (MDP) model, as presented in Section II, attempts to
ﬁll this gap. See [14] for a discussion on MDP models.
A commonly used method for evaluating decision problems
in health care has been “decision tree.” But this method is in-
applicable in cases where decisions are state dependent and
inﬂuence the state transition probabilities [15]. The framework
of MDP was developed by Bellman (1957), and was extended
by Karlin (1955), Howard (1960), Blackwell (1965), to name a
few [14]. MDPmodels have been used in recent years in model-
ing diverse medical decision making problems including organ
transplantation and controlling an epidemic in a closed popu-
lation [15]. There exist well-known algorithms, such as value
iteration, policy iteration, and linear programming, for ﬁnding
optimal policies from MDP models [14], [15].
Our MDP model uses data from recent medical literature
([5] and [11]) on incidence probabilities of various stages of
cancers, utility-weights, availability and cost of interventions,
morbidity, and mortality. The model ﬁnds optimal strategies
by either maximizing the total reward measured in terms of
QALYs, or minimizing the total expected cost of intervention
and treatment. OurMDPmodel is capable of identifying optimal
intervention actions for any state comprising age, health, and
prior intervention status. We considered an expanded and more
realistic state space for identifying health and prior intervention
status of mutation carriers compared to other models in the open
literature. Also in our model, screening option can be turned
on or off at any age, whereas in the published literature, the
screening decision is made only once for all ages.
II. MARKOV DECISION PROCESS MODEL FOR BRCA1/2
MUTATION CARRIERS
We have modeled the yearly state transition process for mu-
tation carriers between ages 30 to 65 as a Markov chain. Sub-
sequently, we have overlayed a decision process model on the
Markov chain to form aMDPmodel. Solution of theMDPmodel
yields the optimal intervention strategy comprising actions at
every state. Components of the discrete-time MDP model are
decision epoch, state space, decision space, transition probabil-
ities, and reward function, which are described next.
Decision epochs are considered to be the beginning of each
new year starting at age 30 till age 65. We deﬁne the state
of a mutation carrier (s) using a three-tuples as s = (a, h, i),
where age a ∈ {30, 31, . . . , 65}, health condition h ∈ {healthy
(hl), breast cancer (bc), ovarian cancer (oc), death from other
causes (de)}, and i indicates the intervention status, which is
explained later. The breast cancer element (bc) of the health con-
dition is represented by a three-tuple as (ER, size, stage) [11],
where ER denotes the estrogen receptor, which can be + or
− size indicates the tumor size given by <2 cm or ≥2 cm,
considered only for the local stage and stage indicates the
clinical diagnosis of the tumor as local (l), regional (r), or
distant (dt). Hence, there are eight possible conditions of the
breast cancer bc element of h, which are {(+, <2, l), (+,≥2, l),
(−, <2, l), (−,≥2, l), (+, r), (−, r), (+, dt), (−, dt)}. Ovarian
cancer (oc) element of the health condition h is not further
broken into different stages for modeling purposes. Hence, the
cardinality of health condition is |h| = 11.
The intervention status i of the state of a mutation carrier is
given by a two-tuple (sc, su), where sc indicates the screen-
ing status and the su indicates the status of preventive surgery.
Screening alternatives are sc ∈ {NSc, Sc}, where NSc is no
screening and Sc is screening with mammography and MRI.
Hence, the cardinality of screening status |sc| = 2. It is con-
sidered that the surgeries can be chosen only at ages 30, 40,
or 50, whereas, screening can be chosen at any age. The al-
ternatives for surgery (su) are as follows. For ages 30 up to
39, the surgical status can be su ∈ {no surgery, PM-30, PO-30,
PM+PO-30}, where PM-30 denotes prophylactic mastectomy
at age 30, and the other elements are deﬁned similarly. Between
the ages 40 and 49, we have su ∈ {no surgery, PM-30, PM-
40, PO-30, PO-40, PM+PO-30, PM+PO-40, PM-30+PO-40,
PM-40+PO-30}. Finally, for ages 50 or greater, the interven-
tion status can be su ∈ {no surgery, PM-30, PM-40, PM-50,
PO-30, PO-40, PO-50, PM+PO-30, PM+PO-40, PM+PO-50,
PM-30+PO-40, PM-40+PO-30, PM-50+PO-30, PM-50+PO-
40, PM-30+PO-50, PM-40+PO-50}. Hence, for ages between
30 to 39 |su| = 4, between 40 to 49 |su| = 9, and for ages
50 to 65 |su| = 16. Therefore, the cardinality of the state
space S = {s} of a mutation carrier can be given as: |S| =
10 ∗ 11 ∗ 2 ∗ 4 + 10 ∗ 11 ∗ 2 ∗ 9 + 16 ∗ 11 ∗ 2 ∗ 16 = 8492.
The available intervention decisions d are considered to be
state dependent. At ages 30, 40, and 50, the decisions are either
do nothing or conduct surgery and/or screening. At all inter-
mediate ages (31–39, 41–49, and 51–65) intervention decisions
are only either do nothing or start/stop screening. Following are
some examples. In state s1 = (30, hl, NSc, no surgery), the set
of possible decision choices isDs1 = {do nothing, Sc, PM, PO,
PM+PO, PM+Sc, PO+Sc, PM+PO+Sc}. In state s2 = (40, hl,
NSc, PM-30), the set of available intervention decisions is Ds2
= {do nothing, Sc, PO, PO+Sc}. In state s3 = (52, hl, Sc, PM-
30+PO-40), the set of possible decisions isDs3 = {do nothing,
NSc}. In what follows, we characterize the random process that
underlie the changes in the state of a mutation carrier.
Let Xa , a ∈ {30, 31, . . . , 65}, denote the state random vari-
able at age a of a mutation carrier. Deﬁne a carrier state
process X = {Xa : a = 30, 31, . . . , 65}. The probability that
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Fig. 1. Sample segment of the one-step state transitions of the MDP model.
a healthy mutation carrier of age a transitions to a particular
state at age a+ 1 depends only on her intervention status and
health condition at age a and independent of the past. Hence,
it can be shown that P (Xa+k = u|Xl, ∀l ≤ a; a+ k ≤ 65) =
P (Xa+k = u|Xa = v), and thus,X is a Markov chain. Let Da
denote the decision choice random variable, which is a func-
tion of the state random variable Xa . Deﬁne D = {Da : a =
30, 31, . . . , 65} as the decision process. Then the joint pro-
cess (X,D) is a MDP. The structure of the one-step transition
probabilities of the Markov chainX is described next.
Fig. 1 shows a small segment of the one-step transition dia-
gram that captures transitions between ages 39–40 and 40–41
under the decisions to do nothing and PM-40, respectively. A
BRCA1/2 mutation carrier who is healthy at age 39 and with
no history of interventions, can transition at age 40 to any of
the health conditions as shown: healthy, breast cancer, ovarian
cancer, death from other causes. If the transition state at age
40 is one of the cancer states, which are considered to be ab-
sorbing states in our model, the carrier undergoes treatment. If
the carrier transitions to healthy state at 40 and decides for PM,
the subsequent transitions possible at age 41 are as shown. The
probabilities of various transitions depend on the type of muta-
tion, age, and type of chosen intervention. Note that the effect
of interventions on the transition probabilities also depend on
at what age the intervention was implemented. For example,
transition probabilities between ages 40 and 41 would be dif-
ferent if PM was chosen at age 30 or at age 40. It was found
in [11] that PM at 30 reduces the incidence of breast cancer at
later ages more than PM at 40. This motivated us to supplement
the notation of the interventions with age (for example: PM-30,
PM+PO-50). Table I exempliﬁes the one-step transitions in our
TABLE I
SAMPLE ONE-STEP TRANSITIONS AND CORRESPONDING PROBABILITIES OF A
BRCA2 MUTATION CARRIER
model by specifying all possible transitions from a particular
state of a BRCA2 carrier at age 40 when the action of NSc and
PO-40 are chosen. The details of how we obtain the probabili-
ties in Table I are given in Table IX of the supplementary web
material.
III. MDP MODEL SOLUTION
We used the discounted value iteration algorithm [16] for
solving our MDP model. Let n denote the iteration count, and
Vn (s) denote the value of state s in the nth iteration. It is shown
in (1) how in every iteration the value of the state is updated,
where r(s, d) is the immediate reward of selecting decision d at
state s, α is the discounting factor, and p(j|s, d) is the one-step
transition probability from state s to j under decision d. The
value iteration algorithm consists of the following steps.
Step 1. Set n = 0 and Vn (s) = 0 ∀s ∈ S.
Step 2. For each state, s ∈ S, update the value by using:
Vn+1(s) = max
d∈Ds
{r(s, d) + (1− α)
∑
j∈S
p(j|s, d)Vn (j)},
∀s ∈ S. (1)
Step 3. Choose strategy π such that:
π(s) = arg max
d∈Ds
{r(s, d) + (1− α)
∑
j∈s
p(j|s, d)Vn+1(j)},
∀s ∈ S. (2)
Set n ← n+ 1.
Step 4. Repeat steps 2 and 3 until ∀s, |Vn+1(s)− Vn (s)| < θ,
where θ is the chosen threshold value for convergence.
Step 5. Return π as the optimal strategy.
Two main input parameters needed in the implementation
of the discounted value iteration algorithm are the one-step
transition probabilities (p(j|s, d)) and the immediate rewards
(r(s, d)). In the following subsections, we provide details of
how these input parameters are obtained.
A. Computation of One-Step Transition Probabilities
We computed the one-step transition probabilities using the
breast and ovarian cancer incidences at speciﬁc ages of 30,
40, till 80 (as given in [5]). Since our model considers yearly
transitions, we used linear interpolation (as done in [17]) to ob-
tain transition probabilities for intermediate ages. As far as the
surgical interventions are concerned, we chose to consider them
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only at ages 30, 40, and 50 (similar to [11]). However, the tran-
sition probabilities resulting from the surgical interventions that
we adopt from [5] are for ages 25, 40, and 50. We used the tran-
sition probabilities resulting from surgical interventions at 30
same as that for 25 in [5]. Transition probabilities from healthy
(hl) to death from other causes (de) are calculated using Berke-
ley mortality database [18]. The mortality rates are reduced by
the rates of death caused by breast and ovarian cancers and then
further adjusted for the side effects of PO using [11], [18], [19].
Since undergoing PO before age 50 has a two-fold increased
risk of cardiovascular disease and a 50% increased risk of osteo-
porotic hip fracture and dementia, we adjusted the probabilities
of death from other causes based on these relative risks [11]. For
ﬁnding the transition probabilities from a healthy state to a breast
cancer state, we used stage and estrogen receptor (ER) propor-
tions from [17]. The probability of transition to the healthy
state is found by subtracting from one the total probabilities
of transition to other states. When surgeries are implemented
at different ages, for example, PM-30 and PO-50, we assumed
that the transition probabilities after PO-50 to be the same as
PM+PO-30.
We considered that the decision to start or stop screening
can be made at any age between ages 30 and 65. Transition
probabilities resulting from the screening decision were adopted
from [5].
B. Reward: Immediate Cost of Intervention
and Treatment Decisions
We considered three types of decisions involving cost:
surgery, screening, and cancer treatment. We also considered
the cost of death from other causes, which considers only the
terminal care cost. Costs of surgeries and screening are assumed
to be state independent and their values are adopted from [13]
and [21]. For example, cost of PO is considered to be same
irrespective of the age it is performed. Cost of cancer treatment
in a given stage depends on direct and indirect costs, probability
of cancer recurrence, and terminal care cost.
As in [11], we used a stage-based classiﬁcation. Stage I is
deﬁned as local and tumor size less than 2 cm. Stage II is deﬁned
as local with tumor size greater than or equal to 2 and some of
regional cases. Some of the more advanced regional cases are
classiﬁed as Stage III. Distant cases are considered stage IV.
Since the regional cases can be classiﬁed either as Stage II or
III, we take the average of the costs as the cost of treatment for
regional cases. The cost Ckb of treating breast cancer in stage
k ∈ {I, II, III, IV } is obtained as
Ckb = [C
k
g + C
k
d + C
k
e + C
k
f ] ∗ (1 + pk1 ) + pk2 ∗ Ct (3)
where the cost of diagnosis of cancer Ckg , includes mammogra-
phy, diagnostic following initialMRI, and the subsequent follow
up MRI, Ckd is the direct cost of treatment, Cke is the indirect
cost of lost income during treatment,Ckf is the cost of follow-up,
and Ct is the terminal care cost of the last year of having breast
cancer. The probability of recurrence in the next ﬁve years, de-
noted by pk1 , is obtained from [11], [22], and the probability of
death from breast cancer in the next ﬁve years, pk2 , is obtained
TABLE II
UTILITY (FOR QALYS) AND COST VALUES
from [21], [23]. Representative values of these costs are adopted
from [13] and [21], which are then adjusted for inﬂation from
2004 to 2013. The calculated costs are shown in Table II.
For stages I and II, we considered that the patients will un-
dergo lumpectomy with axillary dissection, radiotherapy, and
endocrine therapy (only for everyone in two patients) as rec-
ommended in [24]. Based on [21], we assumed a 12 week long
work discontinuity for stages I and II. Stage III and IV treatment
considers mastectomy and adjuvant therapy (depending on es-
trogen receptor (ER) status) [21]. Before age 50, it is estimated
that 40% of patients will use bilateral mastectomy and 60%
will undergo unilateral mastectomy. After age 50, we consider
a 50% chance that patients will choose one of the options [21].
Hence, we used the average cost of unilateral and bilateral
mastectomies.
The cost of treatment for ovarian cancer Co is obtained as
Co = [Cod + C
o
e ] + p
o
2 ∗ Cot
where Cod and Coe are the direct and indirect cost of treating
ovarian cancer, respectively. po2 is probability of death from
ovarian cancer in the next ﬁve years, andCot is the terminal care
cost. All these costs were obtained from [13], [21] and [25] and
further adjusted for inﬂation at rate 3%.
C. Reward: Quality-Adjusted Life Years (QALYs)
Wealso usedQALYs as our reward function. Table II provides
the mean utility weights (also referred to in the literature as
preference rating) that are used to deﬁne the relative value of
each disease state. In order to ﬁnd QALYs for a year of life,
one can multiply the utility value of a given state by 1. The
utility weights are obtained using time-tradeoff rating and other
similar methods discussed in [13] and [20]. Since our decision
epochs are at the beginning of each year, the incremental utility
of theMDP at each step is considered to beQALY [26]. QALYs-
optimal policymaximizes theQALYs for amutation carrier with
no concern for cost.
IV. RESULTS
We solved the MDP model using the value iteration package
available in MATLAB [27] using an Intel dual core with 16 GB
RAM. We used a 3% discount factor based on an assumed rate
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TABLE III
ALL POSSIBLE INTERVENTION STRATEGIES FOR 30 YEAR OLD BRCA1
MUTATION CARRIERS WITH NO PRIOR INTERVENTION
of inﬂation. The computation time was approximately 20 min.
We ﬁrst solved the model using cost as our reward function. For
BRCA1 mutation carriers, Table VI presents the cost-optimal
intervention strategies for ages 30 to 65 (rows) and all possible
prior intervention history (columns). For example, for a BRCA1
mutation carrier who has undergone PO at age 30, at age 40,
PM-40 is recommended as the optimal intervention. Note that,
we assumed that all surgical interventions occur at the beginning
of the year. Following a surgery, either a screening (Sc) or no
screening (NSc) action is chosen for the rest of the year. There-
fore, for the aforementioned scenario, at the beginning of age 40,
her prior intervention history changes to PO-30+PM-40. Refer-
ring to column PO-30+PM-40, no screening is recommended
from 40 to 50, and then yearly screening is recommended for
ages 51–65.
For a 30 year old BRCA1 mutation carrier with no prior
intervention history, the optimal action is to undergo both PM
and PO at age 30 (see row ‘30’ and column ‘none’). Now,
referring to age 30 and column PM+PO-30, no screening is
recommended until age 65.
The cost-optimal intervention strategies for BRCA2mutation
carriers can be found in Table VIII in the supplementary web
material. The optimal strategy for a 30 year old with no prior
intervention is to undergo PO at age 30. This changes the prior
intervention history to column PO-30, which recommends no
screening between ages 30–39. At age 40, PM is recommended,
which modiﬁes the prior intervention history to PO-30+PM-40.
Per this column, no screening is recommended during ages 40–
56, followed by yearly screening till 65. If intervention actions
TABLE IV
COMPARISON OF HEALTH OUTCOME PROBABILITIES BY AGE 70 FOR OPTIMAL
STRATEGIES FROM DIFFERENT MODELS FOR A BRCA1 MUTATION ZCARRIER
are limited to only one surgery at a time, our model recommends
PO at age 30 and PM at age 40 for both mutation carriers.
A recent large international prospective study [3] suggests
that BRCA1 mutation carriers should undergo prophylactic
oophorectomy by age 35 because of the high risk of getting
ovarian cancer. This survival-based study also recommends that
BRCA2 mutation carriers can wait until age 40 safely because
of the lower risk of ovarian cancer. Given this recommenda-
tion and the fact that most women are not willing to undergo
PO during child bearing ages, we examined a scenario via our
cost-based model where PO is not considered before age 40 for
BRCA2 mutation carriers. Our model suggests PM at age 30
and PO at age 50. Even when a BRCA2 mutation carrier delays
PM to age 40, our model still recommends PO at age 50.
We then solved the MDP model using the QALYs as our
reward function. As opposed to the cost-optimal solution that
chooses both surgeries at the same time, QALYs-optimal model
postpones PM to age 50 for BRCA1 and does not recommend
PO at age 30 for BRCA2 mutation carriers. The optimal inter-
vention strategies for a BRCA1 and BRCA2 mutation carrier
can be found in Table V and VII. For a 30 year old BRCA1 mu-
tation carrier with no prior intervention, our model suggests PO
at age 30 following by PM at age 50. The model recommends
yearly screening starting from age 50. For a 30 year old BRCA2
mutation carrier with no prior intervention, the QALYs-model
recommends PM-40 and yearly screening only after age 40.
V. ASSESSMENT AND COMPARISON OF OPTIMAL
INTERVENTION STRATEGIES
We used an online tool in [28] to assess probabilities of health
outcomes by age 70 for several optimal intervention strategies
derived from the MDP model, and compared those with out-
come probabilities from all the other possible (but nonoptimal)
intervention strategies. The outcomes by age 70 are death from
other causes, ovarian cancer, breast cancer, and healthy. We
constructed a set of intervention strategies for BRCA1 mutation
carriers of ages 30, which are shown in Table III. Note that
the outcome assessment tool [28] does not allow consideration
of partial screening strategies. Hence, for MDP recommended
strategies that require partial screening,we have considered their
ﬁxed screening variants for comparison purposes.
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TABLE V
QALYS-OPTIMAL INTERVENTION STRATEGIES FOR BRCA1 MUTATION
CARRIERS OF AGES 30 TO 65
For all strategies in Table III, we obtained health outcome
probabilities by age 70. These are plotted in Fig. 2, for BRCA1
mutation carriers. It may also be noted that the assessment tool
[28] does not allow PO before age 35. Since ourmodel considers
PO starting at age 30, we assumed that the outcome probabilities
of PO-30 are approximated by those of PO-35.
As shown in Fig. 2, the optimal intervention strategy #7
[marked by the vertical line (1)] has the highest probability
of being healthy by age 70 (0.72) and the lowest probability of
incidence of breast cancer (0.05). It also has a low probability
of ovarian cancer (0.07), which is within 1% of the lowest ob-
tained by other strategies, for example, #4 and #5. The optimal
strategy #7 has 16% risk of death from other causes compared
to, for example, 10% for strategy #2. This increase is very much
expected as it is well known that PO increases probability of
death from other causes. The QALYs-optimal strategy #16 has
a probability of 0.59 for being healthy by age 70 and a prob-
ability of 0.08 for ovarian cancer incidence. This strategy also
has a low probability (0.13) of death from other causes which
compares well with the lowest value of 0.1 offered by strategy
#2. The QALYs-optimal strategy has 0.2 probability of breast
cancer incidence compared to 0.05 for the cost-optimal strategy
(#7). Health outcome results for BRCA2 mutation carriers can
be found in Table XI and Fig. 3 provided in supplementary web
material section.
VI. SENSITIVITY ANALYSIS
While examining the effect of normal variations in inter-
vention cost on the cost-optimal strategies, no deviations were
TABLE VI
COST-OPTIMAL INTERVENTION STRATEGIES FOR BRCA1 MUTATION CARRIERS
OF AGES 30 TO 65
observed. Only when we increased the intervention cost by ﬁve
folds for BRCA1 and ten folds for BRCA2, the optimal strat-
egy for a 50 year old BRCA1/2 mutation carrier changed from
PM+PO-50 to PO-50. When the cost increases approached 20
folds, the optimal strategies for both 40 and 50 year olds changed
to screening only. Hence, the strategies derived from the MDP
model are quite robust to cost estimate variations. When we de-
creased the utility weights by one standard deviation for BRCA1
mutation carriers, PO-30+PM-40 changed to PM+PO-30 with
less frequent screening. For BRCA2 no changes in surgery op-
tions were observed with decreased utility. But when we in-
creased the utility weights, lower screening frequencies were
recommended. We conducted a sensitivity analysis for the dis-
count factor in the range of 1%–5%. No signiﬁcant variations
in the results were observed.
VII. DISCUSSION
We extended the Markov chain model presented in [13] to
a Markov decision model (MDP) by ﬁrst considering an ex-
panded state space and then by superimposing a state depen-
dent decision process on the Markov chain. The expanded state
space for health and treatment status of mutation carriers and
the corresponding intervention decision options were developed
using information available in [11]. The solution of our MDP
model yields cost and QALYs-optimal intervention strategies
for healthy BRCA1/2 mutation carriers of age 30 to 65 and
with all possible prior intervention status. In our model, the
screening decision choice is considered each year as opposed to
a one-time decision made at age 25 (as in [11]) or age 35 (as
in [13]). In [13], Markovmodeling withMonte Carlo simulation
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TABLE VII
QALYS-OPTIMAL INTERVENTION STRATEGIES FOR BRCA2 MUTATION
CARRIERS OF AGES 30 TO 65
Fig. 2. Health outcome probabilities by age 70 for different intervention strate-
gies (listed in Table III) for 30 year old BRCA1 mutation carriers.
was implemented to ﬁnd the cost-effective strategies for 35 to
50 year old BRCA1/2 mutation carriers. In [11], a Monte carlo
model simulated life histories of a 1980 birth cohort of 1 000 000
female with BRCA1/2 mutations from age 25 until age 100 or
death.
In our MDP model, we ﬁrst used expected present cost to
ﬁnd cost-optimal intervention strategies. True cost of interven-
tion actions, treatment, and the intervention depended transition
probabilities from healthy to other states play important roles
in yielding the optimal intervention strategies. Since treatment
costs are signiﬁcantly higher than the prevention costs for breast
and ovarian cancers, the model attempts to prevent the incidence
of cancer while also trying to minimize the cost of intervention
decisions.We then used utility weights (that represents the qual-
ity adjusted value of a year of life) to ﬁnd the QALYs-optimal
strategies. For this, the model attempts to maximize QALYs for
a person with any prior intervention history and any age. The
existing simulation based models [11] and [13] are capable of
evaluating a given strategy. Whereas, our MDP model can be
solved optimally to yield intervention strategies comprising op-
timal decisions for every state of a healthy mutation carrier. For
example, our model has 8492 states and each state has between
1 and 8 possible state dependent decision choices. The value it-
eration algorithm is able to identify the optimal decision choice
for each state. Also, as demonstrated through the use of both
cost and QALYs metrics of performance, the MDP model can
accommodate a variety of reward measures, for which optimal
strategies could vary. Another feature of our model is that it is
possible to have an optimal strategy with partial screening. This
is an improvement over strategies with ﬁxed screening only that
were presented earlier to the literature.
We compared our MDP model with models in [11] and [13]
using the health outcome probabilities obtained by the online
tool in [28]. As shown in Table IV for a BRCA1 mutation
carrier, the MDP cost-optimal intervention strategy, when com-
pared to [11], yields the same probabilities of being healthy
(0.72), lower ovarian cancer incidence (0.07), and a slightly
higher probability of breast cancer incidence (0.05) and death
from other causes (0.16). The MDP cost-optimal strategy has
better health outcomes compared to [13] in almost all categories
(see Table IV). The MDP QALYs-optimal intervention strate-
gies yields the lowest probability of death from other causes
and slightly higher probability of cancer outcomes compared to
the other models. A similar comparison for BRCA2 mutation
carriers can be found in supplementary web material in Table X.
According to theNationalCancer Institutewebsite [29], avail-
ability of data on the outcomes of interventions to reduce breast
and ovarian risks in BRCA1/2 mutation carriers is limited.
There exists uncertainties regarding cancer risk associated with
BRCA1/2 mutations [29]. Therefore, management of interven-
tions are done primarily based on expert opinions. We believe
that development of model-based decision tools, as presented
here, can help both policy makers as well as patients to make
more informed intervention decisions. Our model suffers from
the following limitations. Since the one-step transition proba-
bilities were adopted from [11], the deﬁnition of state vector
in our model for a mutation carrier had to be restricted. For
example, we could not consider various stages of ovarian can-
cer and recurrence of breast cancer, as this would require more
granular data, than what is currently available, to generate the
necessary one-step transition probabilities. Ourmodel considers
surgical interventions (PM and PO) only at ages 30, 40, and 50.
Once again, limited availability of one-step transition probabil-
ity data restricted our consideration of surgical interventions in
the intermediate ages.
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